Acrylketone group-containing compound and use thereof
By developing compounds containing a propenone group to activate the KEAP1-NRF2 pathway, the problem of KEAP1 dysfunction in existing technologies has been solved, realizing the potential for restoring oxidative stress balance and treating related diseases.
Patent Information
- Application Number
- PCT/CN2026/095051
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-04-28
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Existing technologies have failed to effectively activate the KEAP1-NRF2 pathway, leading to its abnormal function in cancer, neurodegenerative diseases, and inflammation.
Develop compounds containing propenone groups, and activate the KEAP1-NRF2 pathway by regulating the function of KEAP1, thereby restoring its role in oxidative stress balance.
By activating the KEAP1-NRF2 pathway, oxidative stress balance is restored, which has potential therapeutic effects on cancer, neurodegenerative diseases, and inflammation.
Smart Images

Figure CN2026095051_12112026_PF_FP_ABST
Abstract
Description
Compounds containing a propenoyl group and uses thereof
[0001] Cross-reference to related applications
[0002] This application claims priority to and the benefit of Chinese Patent Application No. 202510582379.X, filed May 7, 2025, Chinese Patent Application No. 202511197491.8, filed August 25, 2025, and Chinese Patent Application No. 202610579467.9, filed April 28, 2026, the entire contents of which are incorporated herein by reference. TECHNICAL FIELD
[0003] The present application belongs to the field of medicinal chemistry, and relates to compounds containing a propenoyl group and uses thereof, in particular to a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical composition containing the compound, and uses thereof in the treatment of diseases. BACKGROUND
[0004] KEAP1 (Kelch-like ECH-associated protein 1) is a substrate recognition subunit of E3 ubiquitin ligase, which maintains the balance of oxidative stress by regulating the ubiquitination and degradation of NRF2 (nuclear factor erythroid 2-related factor 2). The KEAP1-NRF2 pathway plays a key role in metabolic reprogramming, ferroptosis, immune escape, and other processes, and its dysfunction is closely related to cancer, neurodegenerative diseases, inflammation, and the like. Therefore, it is necessary to develop related compounds that activate KEAP1.
[0005] DETAILED DESCRIPTION
[0006] In one aspect, the present application relates to a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,
[0007] wherein,
[0008] X is selected from -CH2-, -N(R 2 )-, -O-, or -S-;
[0009] each R 1 is independently selected from deuterium, halogen, -NH2, -OH, =O, -CN, -C(O)NH2, or the following groups optionally substituted with one or more R 1a C 1-6 alkyl, -OC 1-6 alkyl, -SC 1-6 alkyl, -NH(C 1-6 alkyl), -N(C 1-6 alkyl)2, -C(O)C 1-6 alkyl, -C(O)NHC 1-6alkyl, or -C(O)N(C 1-6 alkyl)2;
[0010] or, two R 1 groups on the same carbon atom, together with the carbon atom on which they are attached, form an optionally substituted C 1a ring; 3-6 cycloalkyl;
[0011] R 2 is selected from H, or the following groups optionally substituted with one or more R 2a groups: C 1-6 alkyl, -C(O)C 1-6 alkyl, -C(O)C 3-6 cycloalkyl, -S(O)C 1-6 alkyl, -S(O)C 3-6 cycloalkyl, -S(O)2C 1-6 alkyl, or -S(O)2C 3-6 cycloalkyl;
[0012] R a , R b , and R c are each independently selected from hydrogen, deuterium, halogen, C 1-6 alkyl, or C 1-6 haloalkyl;
[0013] Y is selected from CH, or N;
[0014] each R 3 is independently selected from deuterium, halogen, -NH2, -OH, -CN, -NO2, or the following groups optionally substituted with one or more R 3a groups: C 1-6 alkyl, -OC 1-6 alkyl, -SC 1-6 alkyl, -NH(C 1-6 alkyl), or -N(C 1-6 alkyl)2;
[0015] L is selected from a bond, -NH-, or -C(O)NH-;
[0016] when L is selected from a bond,
[0017] Ring A is selected from the following groups optionally substituted with one or more R 5 groups: C 6-10 aryl, or 5-12 membered heteroaryl;
[0018] R 4 is selected from the following groups optionally substituted with one or more R 4a groups: C 6-10Aryl, 5-12 membered heteroaryl, 9-12 membered heterocyclic, -NR 4c R 4d 、or -C(O)NR 4c R 4d ;
[0019] Each R 5 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, or optionally influenced by one or more R. 5a The following groups are substituted: C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl)2、-C(O)OC 1-6 Alkyl, -C(O)C 1-6 Alkyl group, -C(O)NHC 1-6 Alkyl, or -C(O)N(C 1-6 Alkyl)2;
[0020] When L is selected from -NH- or -C(O)NH-
[0021] Ring A is selected from any one or more R 6 The following groups are substituted: C 6-10 Aryl, or 5-12 heteroaryl;
[0022] R 4 It does not exist, or is selected from one or more Rs. 4b The following groups are substituted: C 6-10 Aryl, 5-12 membered heteroaryl, 4-12 membered heterocyclic, -NR 4c R 4d 、or -C(O)NR 4c R 4d ;
[0023] Each R 6 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, -C(O)NH2, or optionally by one or more R 6a The following groups are substituted: C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl)2、-C(O)C 1-6 Alkyl, -C(O)OC 1-6 Alkyl group, -C(O)NHC 1-6 Alkyl, -C(O)N(C) 1-6alkyl, -NHC(O)C 1-6 alkyl, -S(O)2C 1-6 alkyl, -S(O)2NHC 1-6 alkyl, -S(O)2N(C 1-6 alkyl)2, -NHS(O)2C 1-6 alkyl, -NHC(O)OC 1-6 alkyl, -NHC(O)NHC 1-6 alkyl, or -NHC(O)N(C 1-6 alkyl)2;
[0024] R 4c each is independently selected from hydrogen, deuterium, or C 1-6 alkyl;
[0025] R 4d each is independently selected from C 2-6 alkenyl, C 2-6 alkynyl, -C 1-6 alkylene-C(O)NHC 1-6 alkyl, -C 1-6 alkylene-C(O)N(C 1-6 alkyl)2, -C 1-6 alkylene-C 3-12 cycloalkyl, -C 1-6 alkylene-3-12 membered heterocycloalkyl, -C 1-6 alkylene-C 6-10 aryl, -C 1-6 alkylene-5-12 membered heteroaryl, C 6-10 aryl, or 5-12 membered heteroaryl;
[0026] each R 1a , R 2a , R 3a , R 4a , R 4b , R 5a , and R 6a are each independently selected from deuterium, halogen, -NH2, -OH, =O, -CN, C 1-6 alkyl, deuterated C 1-6 alkyl, halogenated C 1-6 alkyl, -OC 1-6 alkyl, -SC 1-6 alkyl, -NH(C 1-6 alkyl), -N(C 1-6 alkyl)2, -C(O)C 1-6 alkyl, -C(O)OC 1-6 alkyl, -C(O)NHC 1-6 alkyl, -C(O)N(C 1-6Alkyl)2、-NHC(O)C 1-6 Alkyl group, -S(O)2C 1-6 Alkyl group, -S(O)2NHC 1-6 Alkyl group, -NHS(O)2C 1-6 Alkyl, -NHC(O)OC 1-6 Alkyl group, -NHC(O)NHC 1-6 Alkyl, or -NHC(O)N(C 1-6 Alkyl)2, C 3-6 Cycloalkyl or 3-6 membered heterocyclic groups;
[0027] m is selected from 0, 1, 2, 3, 4, 5, or 6;
[0028] n is selected from 0, 1, 2, 3 or 4.
[0029] In some embodiments, this application relates to compounds of formula (I), their stereoisomers, or pharmaceutically acceptable salts thereof.
[0030] in,
[0031] X is selected from -CH2-, -N(R) 2 -, -O-, or -S-;
[0032] Each R 1 Each is independently selected from deuterium, halogens, -NH2, -OH, =O, -CN, -C(O)NH2, or optionally by one or more R 1a The following groups are substituted: C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl)2、-C(O)C 1-6 Alkyl group, -C(O)NHC 1-6 Alkyl, or -C(O)N(C 1-6 Alkyl)2;
[0033] Or, two R atoms on the same carbon atom 1 Together with the carbon atoms they are attached to, they form optional groups of one or more R atoms. 1a Replacement C 3-6 cycloalkyl;
[0034] R 2 Selected from H, or arbitrarily selected by one or more R 2a The following groups are substituted: C 1-6 Alkyl, -C(O)C 1-6 Alkyl, -C(O)C 3-6 Cycloalkyl, -S(O)C1-6 Alkyl, -S(O)C 3-6 Cycloalkyl, -S(O)2C 1-6 Alkyl group, or -S(O)2C 3-6 cycloalkyl;
[0035] R a R b and R c Each is independently selected from hydrogen, deuterium, halogens, and carbon. 1-6 Alkyl, or C 1-6 Halogenated alkyl groups;
[0036] Y is selected from CH or N;
[0037] Each R 3 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, or optionally influenced by one or more R. 3a Replace the following groups: C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -NH(C) 1-6 alkyl), or -N(C) 1-6 Alkyl)2;
[0038] L is selected from the bond, or -NH-;
[0039] When L is selected from the bond,
[0040] Ring A is selected from any one or more R 5 The following groups are substituted: C 6-10 Aryl, or 5-12 heteroaryl;
[0041] R 4 Selected from one or more R 4a The following groups are substituted: C 6-10 Aryl, 5-12 membered heteroaryl, or 9-12 membered heterocyclic;
[0042] Each R 5 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, or optionally influenced by one or more R. 5a The following groups are substituted: C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -NH(C) 1-6 alkyl), or -N(C) 1-6 Alkyl)2;
[0043] When L is selected from -NH-
[0044] Ring A is selected from any one or more R 6The following groups are substituted: C 6-10 Aryl, or 5-12 heteroaryl;
[0045] R 4 Does not exist or is selected by one or more R 4b The following groups are substituted: C 6-10 Aryl, 5-12 membered heteroaryl, or 4-12 membered heterocyclic;
[0046] Each R 6 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, -C(O)NH2, or optionally by one or more R 6a The following groups are substituted: C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl)2、-C(O)C 1-6 Alkyl, -C(O)OC 1-6 Alkyl group, -C(O)NHC 1-6 Alkyl group, -NHC(O)C 1-6 Alkyl group, -S(O)2C 1-6 Alkyl group, -S(O)2NHC 1-6 Alkyl group, -S(O)2N(C) 1-6 alkyl)2、-NHS(O)2C 1-6 Alkyl, -NHC(O)OC 1-6 Alkyl group, -NHC(O)NHC 1-6 Alkyl, or -NHC(O)N(C 1-6 Alkyl)2;
[0047] Each R 1a R 2a R 3a R 4a R 4b R 5a and R 6a Each is independently selected from deuterium, halogens, -NH2, -OH, =O, -CN, and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl)2, C 3-6 Cycloalkyl or 3-6 membered heterocyclic groups;
[0048] m is selected from 0, 1, 2, 3, 4, 5, or 6;
[0049] n is selected from 0, 1, 2, 3 or 4.
[0050] In some implementations, X is selected from -O-.
[0051] In some implementations, X is selected from -N(R) 2 )-.
[0052] In some implementations, each R 1 Each is independently selected from deuterium, halogens, -NH2, -OH, =O, -CN, -C(O)NH2, or optionally by one or more R 1a The following groups are substituted: C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), -N(C) 1-4 Alkyl)2、-C(O)C 1-4 Alkyl group, -C(O)NHC 1-4 Alkyl, or -C(O)N(C 1-4 Alkyl)2;
[0053] Or, two R atoms on the same carbon atom 1 Together with the carbon atoms they are attached to, they form optional groups of one or more R atoms. 1a Replacement C 3-4 Cycloalkyl.
[0054] In some implementations, each R 1 Each is independently selected from deuterium, halogens, -NH2, -OH, =O, -CN, -C(O)NH2, or optionally by one or more R 1a The following groups may be substituted: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl.
[0055] In some implementations, each R 1 Each is independently selected from deuterium, halogen, -NH2, -OH, =O, -CN, -C(O)NH2, methyl, trifluoromethyl, trideuterated methyl, or hydroxymethyl.
[0056] In some implementations, two R atoms on the same carbon atom 1 Together with the carbon atoms they are attached to, they form optional groups of one or more R atoms. 1a The following groups may be substituted: cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
[0057] In some implementations, each R 1a Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, and C. 1-4Alkyl, deuterated C 1-4 Alkyl, Halogenated C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), or -N(C) 1-4 Alkyl)2.
[0058] In some implementations, each R 1a Each is independently selected from deuterium, halogen, -NH2, -OH, or -CN.
[0059] In some implementations, each R 1a Each can be independently selected from deuterium, -F, -Cl, or -Br.
[0060] In some implementation schemes, R 2 Selected from H, or arbitrarily selected by one or more R 2a The following groups are substituted: C 1-4 Alkyl, -C(O)C 1-4 Alkyl, -C(O)C 3-6 Cycloalkyl, -S(O)C 1-4 Alkyl, -S(O)C 3-6 Cycloalkyl, -S(O)2C 1-4 Alkyl group, or -S(O)2C 3-6 Cycloalkyl.
[0061] In some implementation schemes, R 2 It is selected from H, methyl, ethyl, -C(O)CH3, -C(O)cyclopropane, -S(O)CH3, -S(O)cyclopropane, -S(O)2CH3, or -S(O)2cyclopropane.
[0062] In some implementations, each R 2a Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, and C. 1-4 Alkyl, deuterated C 1-4 Alkyl, Halogenated C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), or -N(C) 1-4 Alkyl)2.
[0063] In some implementations, each R 2a Each is independently selected from deuterium, halogen, -NH2, -OH, or -CN.
[0064] In some implementations, each R 2a Each can be independently selected from deuterium, -F, -Cl, or -Br.
[0065] In some implementation schemes, R a R b and R c Each is independently selected from hydrogen, deuterium, halogens, and carbon. 1-4 Alkyl, or C 1-4 Halogenated alkyl groups.
[0066] In some implementation schemes, R a R b and R c Both are hydrogen.
[0067] In some implementations, Y is selected from CH.
[0068] In some implementations, each R 3 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, or optionally influenced by one or more R. 3a Replace the following groups: C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), or -N(C) 1-4 Alkyl)2.
[0069] In some implementations, each R 3 Each is independently selected from deuterium, halogen, -NH2, -OH, -CN, -NO2, methyl, methoxy, methylthio, methylamino, dimethylamino, trifluoromethyl, trideuterated methyl, or hydroxymethyl.
[0070] In some implementations, each R 3 Each is independently selected from halogens.
[0071] In some implementations, each R 3 Each can be independently selected from -F, -Cl, or -Br.
[0072] In some implementation schemes, R 3 Selected from -Cl.
[0073] In some implementations, each R 3a Each is independently selected from deuterium, halogens, -NH2, -OH, =O, -CN, and C. 1-4 Alkyl, deuterated C 1-4 Alkyl, Halogenated C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), -N(C) 1-4 Alkyl)2, C 3-6Cycloalkyl or 3-6 membered heterocyclic groups.
[0074] In some implementations, each R 3a Each is independently selected from deuterium, halogen, -NH2, -OH, =O, or -CN.
[0075] In some implementations, when L is selected as a key, ring A is selected as optionally being one or more R. 5 The following groups are substituted: C 6-10 Aryl, or 5-9 aryl heteroaryl.
[0076] In some implementations, when L is selected as a key, ring A is selected as optionally being one or more R. 5 The following groups are substituted: phenyl, or 5-6 membered heteroaryl.
[0077] In some implementations, when L is selected as a key, ring A is selected as optionally being one or more R. 5 The following groups are substituted: phenyl, or containing 1-3 5-6 membered heteroaryl groups selected from N heteroatoms.
[0078] In some implementations, when L is selected as a key, ring A is selected as optionally being one or more R. 5 The following groups are substituted: containing 1-3 six-membered heteroaryl groups selected from N heteroatoms.
[0079] In some embodiments, when L is selected as a bond, ring A is selected as a 6-membered heteroaryl group containing 2 or 3 heteroatoms selected from N.
[0080] In some implementations, when L is selected as a bond, ring A is selected as a 6-membered heteroaryl group containing two heteroatoms selected from N.
[0081] In some implementations, when L is selected as a bond, ring A is selected as a 6-membered heteroaryl group containing 3 heteroatoms selected from N.
[0082] In some embodiments, when L is selected from a bond, ring A is selected from pyrimidinyl or 1,3,5-triazineyl.
[0083] In some implementations, when L is selected from a bond, the ring A is selected from a pyrimidinyl group.
[0084] In some embodiments, when L is selected from a bond, ring A is selected from 1,3,5-triazine.
[0085] In some implementations, when L is selected from the key, ring A is selected from... The asterisk (*) represents the end connected to L.
[0086] In some implementations, when L is selected from the key, ring A is selected from... The asterisk (*) represents the end connected to L.
[0087] In some implementations, when L is selected from the key, ring A is selected from... The asterisk (*) represents the end connected to L.
[0088] In some implementations, each R 5 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, or optionally influenced by one or more R. 5a The following groups are substituted: C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), or -N(C) 1-4 Alkyl)2. In some embodiments, each R 5 Each is independently selected from one or more R options. 5a The following groups are substituted: -C(O)OC 1-4 Alkyl, -C(O)C 1-4 Alkyl group, -C(O)NHC 1-4 Alkyl, or -C(O)N(C 1-4 Alkyl)2.
[0089] In some implementations, each R 5 Each is independently selected from deuterium, -F, -Cl, -Br, -NH2, -OH, -CN, -NO2, or optionally influenced by one or more R groups. 5a The following groups may be substituted: methyl, ethyl, n-propyl, or isopropyl.
[0090] In some implementations, each R 5a Each is independently selected from deuterium, halogens, -NH2, -OH, =O, -CN, and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 alkyl.
[0091] In some implementations, each R 5a Each is independently selected from deuterium, halogens, -NH2, -OH, or =O.
[0092] In some implementations, when L is selected as a key, R 4 Selected from one or more R 4a The following groups are substituted: C 6-10 Aryl, 5-6 nucleotide monocyclic heteroaryl, 8-12 nucleotide bicyclic heteroaryl, 9-12 nucleotide bicyclic heterocyclic, -NHR 4d 、or -C(O)NHR 4d .
[0093] In some implementations, when L is selected as a key, R4 Selected from one or more R 4a The following groups are substituted: C 6-10 Aryl, 5-6 member monocyclic heteroaryl, 8-12 member bicyclic heteroaryl, or 9-12 member bicyclic heterocyclic group.
[0094] In some implementations, when L is selected as a key, R 4 Selected from one or more R 4a The following groups are substituted: 5-6 membered monocyclic heteroaryl, 9-10 membered bicyclic heteroaryl, or 9-10 membered bicyclic heterocyclic group.
[0095] In some implementations, when L is selected as a key, R 4 Selected from one or more R 4a The following groups are substituted: 5-6 membered monocyclic heteroaryl, 9-10 membered bicyclic heteroaryl, or 9-10 membered bicyclic heterocyclic alkenyl.
[0096] In some implementations, when L is selected as a key, R 4 Selected from one or more R 4a Substituted 5-6 membered monocyclic heteroaryl groups. In some embodiments, when L is selected from the bond, R... 4 Selected from one or more R 4a The substituted 9-10 membered bicyclic heteroaryl group. In some embodiments, when L is selected from the bond, R... 4 Selected from one or more R 4a Substituted 9-10 membered bicyclic heterocyclic alkenyl groups.
[0097] In some implementations, when L is selected as a key, R 4 Selected from one or more R 4a The following groups may be substituted: 5-6 membered monocyclic heteroaryl groups containing 1-3 heteroatoms selected from N, O or S; 9-10 membered bicyclic heteroaryl groups containing 1-5 heteroatoms selected from N, O or S; or 9-10 membered bicyclic heterocyclic diaryl groups containing 1-5 heteroatoms selected from N, O or S.
[0098] In some implementations, when L is selected as a key, R 4 Selected from one or more R 4a The following groups may be substituted: containing 1-3 5-6 membered monocyclic heteroaryl groups selected from N heteroatoms, containing 1-5 9-10 membered bicyclic heteroaryl groups selected from N heteroatoms, or containing 1-5 9-10 membered bicyclic heterocyclic diaryl groups selected from N heteroatoms.
[0099] In some implementations, when L is selected as a key, R 4 Selected from one or more R 4a The following groups are substituted:
[0100] In some implementations, when L is selected as a key, R 4 Selected from one or more R 4a The following groups are substituted: In some implementations, when L is selected as a key, R 4 Selected from one or more R 4a The following groups are substituted: In some implementations, when L is selected as a key, R 4 Selected from one or more R 4a The following groups are substituted:
[0101] In some implementations, when L is selected as a key, R 4 Selected from one or more R 4a The following groups are substituted: In some implementations, when L is selected as a key, R 4 Selected from one or more R 4a The following groups are substituted: In some implementations, when L is selected as a key, R 4 Selected from one or more R 4a The following groups are substituted: In some implementations, when L is selected as a key, R 4 Selected from one or more R 4a The following groups are substituted
[0102] In some implementations, when L is selected as a key, R 4 Selected from
[0103] In some implementations, when L is selected as a key, R 4 Selected from one or more R 4a The following groups are substituted: -NR 4c R 4d 、or -C(O)NR 4c R 4d .
[0104] In some implementation schemes, R 4c Each is independently selected from hydrogen, deuterium, or C.1-4 alkyl.
[0105] In some implementation schemes, R 4c Each is independently selected from hydrogen, methyl, ethyl, n-propyl, or isopropyl.
[0106] In some implementation schemes, R 4c Each is independently selected from hydrogen.
[0107] In some implementation schemes, R 4d Each was independently selected from C 2-4 alkenyl, C 2-4 alkynyl group, -C 1-4 Alkylene-C(O)NH(C) 1-4 Alkyl), -C 1-4 Alkylene-C(O)N(C) 1-4 Alkyl)2, -C 1-4 Alkylene-C 3-6 cycloalkyl, -C 1-4 Alkylene-3-6-membered heterocyclic alkyl, -C 1-4 alkylene-phenyl, -C 1-4 Alkylene-5-6 heteroaryl, phenyl, or 5-6 heteroaryl.
[0108] In some implementation schemes, R 4d Each was independently selected from C 2-6 alkenyl, C 2-6 alkynyl group, -C 1-6 Alkylene-C(O)NH(C) 1-6 Alkyl), -C 1-6 Alkylene-C 3-12 cycloalkyl, -C 1-6 Alkylene-3-12-membered heterocyclic alkyl, -C 1-6 Alkylene-C 6-10 Aryl, C 6-10 Aryl, or 5-12 heteroaryl.
[0109] In some implementation schemes, R 4d Each was independently selected from C 2-4 alkenyl, C 2-4 alkynyl group, -C 1-4 Alkylene-C(O)NH(C) 1-4 Alkyl), -C 1-4 Alkylene-C 3-6 cycloalkyl, -C 1-4 Alkylene-3-6-membered heterocyclic alkyl, -C 1-4 Alkylene-phenyl, phenyl, or 5-6 heteroaryl.
[0110] In some embodiments, the heterocyclic alkyl and heteroaryl groups contain one, two, or three heteroatoms selected from N, O, or S.
[0111] In some implementations, each R 4d Each is independently selected from vinyl, propenyl, butenyl, ethynyl, propynyl, butynyl, -CH2C(O)NHCH3, -CH2C(O)NHCH2CH3, -CH2CH2C(O)NHCH3, -CH2CH2C(O)NHCH2CH3, -methylenecyclopropyl, -ethylcyclopropyl, -methylenecyclobutyl, -ethylcyclobutyl, -methylenecyclopentyl, -ethylcyclopentyl, -methylenetetrahydrofuranyl, -ethyltetrahydrofuranyl, -methylenetetrahydropyrrolyl, -ethyltetrahydropyrrolyl, -methylenetetrahydropyrrolyl, -ethyltetrahydropyrrolyl, -ethyltetrahydropyrrolyl, -methylenepiperidinyl, -ethylpiperidinyl, -methylenephenyl, -ethylphenyl, -methylenepyridinyl, -ethylpyridinyl, phenyl, or pyridine.
[0112] In some implementations, each R 4d Each independently selected
[0113] In some implementation schemes, R 4 Selected from one or more R 4a Replacement -NR 4c R 4d R 4d Selected from C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkylene-C(O)NH(C) 1-6 Alkyl), -C 1-6 Alkylene-C 3-12 cycloalkyl, -C 1-6 Alkylene-3-12-membered heterocyclic alkyl, -C 1-6 Alkylene-C 6-10 Aryl.
[0114] In some implementation schemes, R 4 Selected from one or more R 4a Substituted -C(O)NR 4c R 4d R 4d Selected from C 6-10 Aryl, or 5-12 heteroaryl.
[0115] In some implementation schemes, R 4 Selected from one or more R 4a The following groups are substituted:
[0116] In some implementations, each R 4a Each is independently selected from deuterium, halogens, -NH2, -OH, =O, -CN, and C. 1-4 Alkyl, deuterated C 1-4 Alkyl, Halogenated C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), -N(C) 1-4 Alkyl)2、-C(O)C 1-6 Alkyl, -C(O)OC 1-4 Alkyl group, -C(O)NHC 1-4 Alkyl group, -S(O)2C 1-4 Alkyl group, -S(O)2NHC 1-4 Alkyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic groups.
[0117] In some implementations, each R 4a Each is independently selected from deuterium, halogens, -NH2, -OH, =O, -CN, and C. 1-4 Alkyl, deuterated C 1-4 Alkyl, Halogenated C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), -N(C) 1-4 Alkyl)2, C 3-6 Cycloalkyl or 3-6 membered heterocyclic groups.
[0118] In some implementations, each R 4a Each R is independently selected from deuterium, -F, -Cl, -Br, -NH2, -OH, =O, -CN, methyl, ethyl, n-propyl, isopropyl, -CD3, -CF3, -CH2CF3, -OCH3, or -OCH2CH3. In some embodiments, each R 4a Each is independently selected from -C(O)OCH3, -C(O)OCH2CH3, -C(O)NHCH3, or -C(O)N(CH3)2.
[0119] In some implementations, each R 4a Each is independently selected from deuterium, -F, -Cl, -Br, -NH2, -OH, =O, -CN, methyl, -CF3, -CH2CF3, -OCH3, or -C(O)OCH3.
[0120] In some implementations, when L is selected as a key, R4 Selected from
[0121] In some implementations, when L is selected as a key, R 4 Selected from
[0122] In some implementations, when L is selected as a key, R 4 Selected from
[0123] In some implementations, when L is selected as a key, R 4 Selected from
[0124] In some implementations, when L is selected as a key, R 4 Selected from
[0125] In some embodiments, when L is selected from -NH- or -C(O)NH-, ring A is selected from one or more R-. 6 The following groups are substituted: C 6-10 Aryl, or 5-10 heteroaryl.
[0126] In some embodiments, when L is selected from -NH- or -C(O)NH-, ring A is selected from one or more R-. 6 The following groups may be substituted: phenyl, naphthyl, 5-6 membered monocyclic heteroaryl containing 1-3 heteroatoms selected from N, O, or S, and 9-10 membered bicyclic heteroaryl containing 1-5 heteroatoms selected from N, O, or S.
[0127] In some embodiments, when L is selected from -NH- or -C(O)NH-, ring A is selected from one or more R-. 6 The following groups may be substituted: phenyl, naphthyl, 5-6 membered monocyclic heteroaryl groups containing 1-3 N heteroatoms, and 9-10 membered bicyclic heteroaryl groups containing 1-5 N heteroatoms.
[0128] In some embodiments, when L is selected from -NH- or -C(O)NH-, ring A is selected from one or more R-. 6 The following groups may be substituted: phenyl, naphthyl, 6-membered monocyclic heteroaryl containing 1-3 N heteroatoms, and 9-membered bicyclic heteroaryl containing 1-5 N heteroatoms.
[0129] In some embodiments, when L is selected from -NH- or -C(O)NH-, ring A is selected from one or more R-.6 The following groups are substituted: phenyl, pyridyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl.
[0130] In some embodiments, when L is selected from -NH- or -C(O)NH-, ring A is selected from one or more R-. 6 The following groups are substituted: The asterisk (*) represents the end connected to L.
[0131] In some implementations, when L is selected from -NH- or -C(O)NH-, R 4 Does not exist or is selected by one or more R 4b The following groups are substituted: C 6-10 Aryl, 5-10 heteroaryl, or 4-10 heterocyclic.
[0132] In some implementations, when L is selected from -NH- or -C(O)NH-, R 4 Does not exist or is selected by one or more R 4b The following groups may be substituted: phenyl, 5-6 membered monocyclic heteroaryl containing 1-3 heteroatoms independently selected from N, O, or S, 9-10 membered bicyclic heteroaryl containing 1-5 heteroatoms independently selected from N, O, or S, 4-7 membered monocyclic heterocyclic alkenyl containing 1-3 heteroatoms independently selected from N, O, or S, 8-10 membered bicyclic heterocyclic alkenyl containing 1-5 heteroatoms independently selected from N, O, or S, or 4-12 membered heterocyclic alkyl containing 1-5 heteroatoms independently selected from N, O, or S.
[0133] In some implementations, when L is selected from -NH- or -C(O)NH-, R 4 Does not exist or is selected by one or more R 4b The following groups are substituted: -NR 4c R 4d 、or -C(O)NR 4c R 4d .
[0134] In some implementations, when L is selected from -NH- or -C(O)NH-, R 4 Does not exist or is selected by one or more R 4b The following groups are substituted: -NHR 4d 、or -C(O)NHR 4d .
[0135] In some implementations, when L is selected from -NH- or -C(O)NH-, R 4 It does not exist.
[0136] In some implementations, each R 6 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, -C(O)NH2, or optionally by one or more R 6a The following groups are substituted: C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), -N(C) 1-4 Alkyl)2、-C(O)C 1-4 Alkyl, -C(O)OC 1-4 Alkyl group, -C(O)NHC 1-4 Alkyl, -C(O)N(C) 1-4 Alkyl)2、-NHC(O)C 1-4 Alkyl group, -S(O)2C 1-4 Alkyl group, -S(O)2NHC 1-4 Alkyl group, -S(O)2N(C) 1-4 alkyl)2、-NHS(O)2C 1-4 Alkyl, -NHC(O)OC 1-4 Alkyl group, -NHC(O)NHC 1-4 Alkyl, or -NHC(O)N(C 1-4 Alkyl)2.
[0137] In some implementations, each R 6 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, -C(O)NH2, or optionally by one or more R 6a The following groups are substituted: C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), -N(C) 1-4 Alkyl)2、-C(O)C 1-4 Alkyl, -C(O)OC 1-4 Alkyl group, -C(O)NHC 1-4 Alkyl group, -NHC(O)C 1-4 Alkyl group, -S(O)2C 1-4 Alkyl group, -S(O)2NHC 1-4 Alkyl group, -NHS(O)2C 1-4 Alkyl, -NHC(O)OC 1-4 Alkyl group, -NHC(O)NHC 1-4 Alkyl, or -NHC(O)N(C 1-4 Alkyl)2.
[0138] In some implementations, each R 6 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, -C(O)NH2, or optionally by one or more R 6a The following groups may be substituted: methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, -SCH3, -SCH2CH3, -NH(CH3), -NH(CH2CH3), -NCH3(CH2CH3), -N(CH2CH3)2, -C(O)CH3, -C(O)OCH3, -C(O)NHCH3, -NHC(O)CH3, -S(O)2CH3, -S(O)2NHCH3, -NHS(O)2CH3, -NHC(O)OCH3, -NHC(O)NHCH3, or -NHC(O)N(CH3)2.
[0139] In some implementations, each R 6 Each is independently selected from -C(O)NHCH2CH3, -C(O)N(CH3)2, -C(O)N(CH2CH3)2, or -C(O)N(CH3)(CH2CH3).
[0140] In some implementations, each R 6a Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, and C. 1-4 Alkyl, deuterated C 1-4 Alkyl, Halogenated C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), -N(C) 1-4 Alkyl)2, C 3-6 Cycloalkyl or 3-6 membered heterocyclic groups.
[0141] In some implementations, each R 6a Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, and C. 1-4 Alkyl, deuterated C 1-4 Alkyl or halogenated C 1-4 alkyl.
[0142] In some implementations, each R 6a Each is independently selected from deuterium, -F, -Cl, -Br, or -NH2.
[0143] In some implementations, each R 6Each is independently selected from deuterium, -F, -Cl, -Br, -NH2, -C(O)NH2, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, hydroxymethyl, methoxy, trifluoromethoxy, ethoxy, -NH(CH3), -NH(CH2CH3), -N(CH3)2, -NCH3(CH2CH3), or -N(CH2CH3)2.
[0144] In some implementations, each R 6 Each is independently selected from -C(O)NHCH3, -C(O)NHCH2CH3, -C(O)N(CH3)2, -C(O)N(CH2CH3)2, or -C(O)N(CH3)(CH2CH3).
[0145] In some implementations, each R 6 Each is independently selected from deuterium, -F, -Cl, -NH2, -C(O)NH2, methyl, methoxy, -NH(CH3), -C(O)NHCH3, or -C(O)N(CH3)2.
[0146] In some implementations, when L is selected from -NH- or -C(O)NH-, R 4 It does not exist.
[0147] Ring A is selected from
[0148] In some implementations, when L is selected from -NH- or -C(O)NH-, R 4 It does not exist.
[0149] Ring A is selected from
[0150] In some implementations, when L is selected from -NH- or -C(O)NH-, R 4 It does not exist.
[0151] Ring A is selected from
[0152] In some implementations, when L is selected from -NH- or -C(O)NH-, R 4 It does not exist.
[0153] Ring A is selected from
[0154] In some embodiments, L is selected from -C(O)NH-, including -C(O)NH-# and #-C(O)NH-, where "#" represents the end connected to ring A. In some embodiments, L is selected from -C(O)NH-#, where "#" represents the end connected to ring A.
[0155] Depending on the different cases of L, the R described in this application 4c and R 4d It can be arbitrarily controlled by one or more R 4a Replace or optionally be one or more R 4b replace.
[0156] In some implementations, m is selected from 0, 1, or 2.
[0157] In some implementations, m is selected from 0.
[0158] In some implementations, n is selected from 0, 1, or 2.
[0159] In some implementations, n is selected from 1.
[0160] In some embodiments, the heterocyclic group is selected from heterocyclic alkyl or heterocyclic alkenyl groups.
[0161] In some embodiments, the heteroaryl, heterocyclic, heterocyclic alkyl, or heterocyclic alkenyl group contains 1, 2, 3, 4, 5, or 6 heteroatoms selected from N, O, or S. In some embodiments, the heteroaryl, heterocyclic, heterocyclic alkyl, or heterocyclic alkenyl group contains 1, 2, 3, or 4 heteroatoms selected from N, O, or S. In some embodiments, the heteroaryl, heterocyclic, heterocyclic alkyl, or heterocyclic alkenyl group contains 1, 2, 3, or 4 heteroatoms selected from N. In some embodiments, the heteroaryl, heterocyclic, heterocyclic alkyl, or heterocyclic alkenyl group contains 1, 2, or 3 heteroatoms selected from N.
[0162] In some embodiments, the compound of formula (I), its stereoisomers, or pharmaceutically acceptable salts thereof are selected from compounds of formula (I'), (II-A), (II'-A), (II-B), (II'-B), (II-C), (II'-C), their stereoisomers, or pharmaceutically acceptable salts thereof.
[0163] in,
[0164] R 1 R a R b R c R 3 R 4The definitions of X, Y, ring A, m, and n are as described above.
[0165] In some embodiments, the compound of formula (I), its stereoisomers, or pharmaceutically acceptable salts thereof are selected from compounds of formula (III-A), (III'-A), (III-B), (III'-B), (III-C), (III'-C), their stereoisomers, or pharmaceutically acceptable salts thereof.
[0166] in,
[0167] R 1 R a R b R c R 3 R 4 The definitions of Y, ring A, and m are as described above.
[0168] In some implementations, this application includes the variables defined above and their implementations, as well as any combination thereof.
[0169] In some embodiments, this application also provides the following compounds, their stereoisomers, or pharmaceutically acceptable salts thereof:
[0170] In some embodiments, this application also provides the following compounds, their stereoisomers, or pharmaceutically acceptable salts thereof:
[0171] On the other hand, this application provides pharmaceutical compositions comprising the above-described compounds of this application, their stereoisomers, or pharmaceutically acceptable salts thereof. In some embodiments, the pharmaceutical compositions of this application further include pharmaceutically acceptable excipients.
[0172] In some embodiments, the pharmaceutical composition of this application comprises 0.01 mg to 2000 mg of the compound of this application, its stereoisomers, or pharmaceutically acceptable salts thereof.
[0173] In some embodiments, the pharmaceutical composition of this application is an oral pharmaceutical composition. In some embodiments, the pharmaceutical composition of this application is a solid pharmaceutical composition.
[0174] On the other hand, this application provides a method for treating mammalian diseases, comprising administering to a mammal, preferably a human, a therapeutically effective amount of the above-mentioned compound, its stereoisomer, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
[0175] On the other hand, this application provides the use of the above-mentioned compounds, their stereoisomers, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the preparation of medicaments for treating diseases.
[0176] On the other hand, this application provides the use of the above-mentioned compounds, their stereoisomers, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the treatment of diseases.
[0177] On the other hand, this application provides the above-mentioned compounds for treating diseases, their stereoisomers, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.
[0178] In some embodiments, the disease is selected from KEAP1-related diseases. In some embodiments, the disease is selected from KEAP1-mediated diseases.
[0179] In some embodiments, the disease is selected from those associated with Nrf2 inhibition by activating KEAP1. In some embodiments, the disease is selected from those mediated by Nrf2 inhibition by activating KEAP1.
[0180] In some embodiments, the disease is selected from cancer. In some embodiments, the KEAP1-related disease is selected from cancer. In some embodiments, the KEAP1-mediated disease is selected from cancer.
[0181] In some embodiments, the cancer is selected from squamous cell carcinoma. In some embodiments, the cancer is selected from esophageal cancer.
[0182] On the other hand, this application provides a method for preparing compounds of formula (I), their stereoisomers, or pharmaceutically acceptable salts thereof, including the reaction of formulas (I-3) and (M) under a catalyst.
[0183] Among them, R 1 R 3 R 4 R a R b R c The definitions of X, Y, L, m, n and ring A are as described in this application;
[0184] LG is a leaving group; for example, LG can be independently selected from -Cl and -Br.
[0185] R XSelected from halogens, such as R X Selected from -Cl and -Br.
[0186] In some embodiments, the catalyst is selected from palladium catalysts.
[0187] In some embodiments, the palladium catalyst is selected from tetraphenylphosphine palladium, palladium chloride, palladium acetate, bis(diphenylphosphine)ferrocene palladium dichloride, etc.
[0188] On the other hand, this application provides a method for preparing compounds of formula (I), their stereoisomers, or pharmaceutically acceptable salts thereof, including condensation reactions of formulas (I-4) and (N) in organic solvents.
[0189] Among them, R 1 R 3 R 4 R a R b R c The definitions of X, Y, L, m, n and ring A are as described in this application;
[0190] LG is a leaving group; for example, LG can be independently selected from -Cl and -Br.
[0191] R X Selected from halogens, such as R X Selected from -Cl and -Br.
[0192] In some embodiments, the condensation reaction is carried out under alkaline conditions, wherein the alkaline base is selected from organic or inorganic bases.
[0193] In some embodiments, the organic base is N,N-diisopropylethylamine, triethylamine, etc.; the inorganic base is selected from sodium carbonate, potassium carbonate, etc.
[0194] The compound, its stereoisomer, or a pharmaceutically acceptable salt thereof exhibits activating activity against KEAP1 and NRF2 protein degradation activity; and also demonstrates good in vitro liver microsomal stability, in vivo (e.g., mouse, rat, dog) pharmacokinetic properties (e.g., AUC), and inhibitory effect on subcutaneous xenografts.
[0195] definition
[0196] Unless otherwise stated, the following terms as used in this application shall have the following meanings. A particular term should not be considered uncertain or unclear unless specifically defined, but should be understood in accordance with its ordinary meaning in the art. When a trade name appears herein, it is intended to refer to the corresponding product or its active ingredient.
[0197] The term "substitution" refers to the substitution of one or more hydrogen atoms on a specific atom by a substituent, provided that the valence state of the specific atom is normal and the resulting compound is stable. When the substituent is oxo (i.e., =O), it means that two hydrogen atoms are substituted; oxo substitution does not occur on aromatic groups.
[0198] The terms “optional” or “optionally” mean that the event or condition described below may or may not occur, including both the occurrence and non-occurrence of the event or condition. For example, the ethyl group “optionally” being halogenated means that the ethyl group can be unsubstituted (CH2CH3), monosubstituted (e.g., CH2CH2F), polysubstituted (e.g., CHFCH2F, CH2CHF2, etc.), or fully substituted (CF2CF3). Those skilled in the art will understand that for any group containing one or more substituents, no substitution or substitution pattern that is spatially impossible and / or cannot be synthesized is introduced.
[0199] The "substituents" mentioned in this article are selected from deuterium, oxo, thio, halogen, hydroxyl, mercapto, amino, nitro, nitroso, cyano, -COOH, -CHO, -C(O)NH2, -S(O)2NH2, C 1-12 Alkyl, C 2-12 alkenyl, C 2-12 alkynyl group, C 1-12 Alkoxy, C 1-12 Alkylthio, C 1-12 Alkylamino, diC 1-12 Alkylamino, 3-12 membered cycloalkyl, 3-12 membered cycloalkyloxy, 3-12 membered cycloalkylthio, 3-12 membered cycloalkylC 1-6 Alkylene, 3-12 membered cycloalkyl C 1-6 Alkoxy, 3-12 membered cycloalkyl C 1-6 Alkylthio, 3-12 membered cycloalkenyl, 3-12 membered cycloalkenyloxy, 3-12 membered cycloalkenylthio, 3-12 membered cycloalkenyl C 1-6 Alkylene, 3-12 membered cycloalkenyl C 1-6 Alkoxy, 3-12 membered cycloalkenyl C 1-6 Alkylthio, 8-12 membered cycloalkynyl, 8-12 membered cycloalkynyloxy, 8-12 membered cycloalkynylthio, 8-12 membered cycloalkynylC 1-6 Alkylene, 8-12 membered cycloalkynyl C 1-6 Alkoxy, 8-12 membered cycloalkynyl C 1-6 Alkylthio, 6-10 aryl, 6-10 aryloxy, 6-10 arylthio, 6-10 arylC 1-6 Alkylene, 6-10 aryl C 1-6 Alkoxy, 6-10 aryl C 1-6Alkylthio, 5-10 heteroaryl, 5-10 heteroaryloxy, 5-10 heteroarylthio, 5-10 heteroarylalkylene, 5-10 heteroarylalkoxy, 5-10 heteroarylalkylthio, 3-12 heterocyclic, 3-12 heterocyclic oxy, 3-12 heterocyclic thio, 3-12 heterocyclic C 1-6 Alkylene, 3-12 membered heterocyclic C 1-6 Alkoxy, 3-12 membered heterocyclic C 1-6 Alkylthio, -C(O)-C 1-12 Alkyl, -S(O)-C 1-12 Alkyl, -S(O)2-C 1-12 Alkyl, -C(O)OC 1-12 Alkyl, -OC(O)-C 1-12 Alkyl group, -C(O)NH-C 1-12 Alkyl, -C(O)N(C) 1-12 Alkyl)2、-NHC(O)-C 1-12 Alkyl group, -S(O)2NH-C 1-12 Alkyl group, -S(O)2N(C) 1-12 alkyl)2、-NHC(O)NH-C 1-12Alkyl, -C(O)- (3-12 membered cycloalkyl), -S(O)- (3-12 membered cycloalkyl), -S(O)2- (3-12 membered cycloalkyl), -C(O)O- (3-12 membered cycloalkyl), -OC(O)- (3-12 membered cycloalkyl), -C(O)NH- (3-12 membered cycloalkyl), -NHC(O)- (3-12 membered cycloalkyl), -S(O)2NH- (3-12 membered cycloalkyl), -NHC(O)NH- (3-12 membered cycloalkyl) cycloalkyl), -C(O)-(6-10 aryl), -S(O)-(6-10 aryl), -S(O)2-(6-10 aryl), -C(O)O-(6-10 aryl), -OC(O)-(6-10 aryl), -C(O)NH-(6-10 aryl), -NHC(O)-(6-10 aryl), -S(O)2NH-(6-10 aryl), -NHC(O)NH-(6-10 aryl), -C( -S(O)-(5-10-membered heteroaryl), -S(O)-(5-10-membered heteroaryl), -S(O)2-(5-10-membered heteroaryl), -C(O)O-(5-10-membered heteroaryl), -OC(O)-(5-10-membered heteroaryl), -C(O)NH-(5-10-membered heteroaryl), -NHC(O)-(5-10-membered heteroaryl), -S(O)2NH-(5-10-membered heteroaryl), -NHC(O)NH-(5-10-membered heteroaryl), - The substituents are C(O)-(3-12 membered heterocyclic group), -S(O)-(3-12 membered heterocyclic group), -S(O)2-(3-12 membered heterocyclic group), -C(O)O-(3-12 membered heterocyclic group), -OC(O)-(3-12 membered heterocyclic group), -C(O)NH-(3-12 membered heterocyclic group), -NHC(O)-(3-12 membered heterocyclic group), -S(O)2NH-(3-12 membered heterocyclic group), and -NHC(O)NH-(3-12 membered heterocyclic group). The substituents are optionally substituted with one or more groups selected from deuterium, oxo, halogen, hydroxyl, mercapto, amino, nitro, cyano, methyl, ethyl, methoxy, methylamino, dimethylamino, etc. In the embodiments described herein, the above-described general formula compound or specific compound or structural fragment or group may optionally be substituted with one or more of the above-described substituents.
[0200] In this document, "one or more" refers to an integer from one to ten. For example, "one or more" means one, two, three, four, five, six, seven, eight, nine, or ten; or, "one or more" means one, two, three, four, five, or six; or, "one or more" means one, two, or three. Those skilled in the art will understand that for any group containing one or more substituents, no substitution or substitution pattern that is spatially impossible and / or cannot be synthesized is introduced.
[0201] C in this article m-n This means that the part has an integer number of carbon atoms within a given range. For example, "C 1-6 "" means that the group can have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms.
[0202] When any variable (e.g., R) appears more than once in the composition or structure of a compound, its definition is independent in each case. Therefore, for example, if a group is substituted by two Rs, each R has an independent option.
[0203] When the number of a linking group is 0, such as -(CH2)0-, it indicates that the linking group is a covalent bond.
[0204] When one of the variables is selected as a covalent bond, it means that the two groups it connects are directly connected. For example, when L in ALZ represents a covalent bond, it means that the structure is actually AZ.
[0205] When a substituent is cross-bonded to two atoms on a ring, it can bond to any atom on that ring. For example, structural units. This indicates that it can be substituted at any position on the cyclohexyl group or cyclohexadiene. For example, for the fragment... Optionally, R 1 It can replace X; for fragments Optionally, R 3 It can replace Y.
[0206] The term "halogen" or "halogen" refers to fluorine, chlorine, bromine, and iodine.
[0207] The term "alkyl" refers to a compound with the general formula C1. n H 2n+1 The alkyl group. This alkyl group can be straight-chain or branched. For example, the term "C 1-6 "Alkyl" refers to an alkyl group containing 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, hexyl, 2-methylpentyl, etc.). Similarly, the alkyl moiety of alkoxy, alkylamino, dialkylamino, alkylsulfonyl, and alkylthio groups (i.e., alkyl groups) has the same definition as above. The alkyl group may optionally be substituted with one or more substituents as described herein.
[0208] The term "alkoxy" refers to -O-alkyl, typically having 1 to 12, 1 to 8, 1 to 6, 1 to 4, 1 to 3, or 1 to 2 carbon atoms. The term "alkathio" refers to -S-alkyl, typically having 1 to 12, 1 to 8, 1 to 6, 1 to 4, 1 to 3, or 1 to 2 carbon atoms. The term "alkylamino" refers to -NH-alkyl, typically having 1 to 12, 1 to 8, 1 to 6, 1 to 4, 1 to 3, or 1 to 2 carbon atoms. The term "dialkylamino" refers to -N(alkyl)2, typically having 1 to 12, 1 to 8, 1 to 6, 1 to 4, 1 to 3, or 1 to 2 carbon atoms.
[0209] The term "alkenyl" refers to an unsaturated aliphatic hydrocarbon group consisting of a straight or branched chain of carbon and hydrogen atoms, having at least one double bond. Non-limiting examples of alkenyl groups include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl, 1,3-butadienyl, etc. The alkenyl group may optionally be substituted with one or more substituents as described herein.
[0210] The term "alkynyl" refers to an unsaturated aliphatic hydrocarbon group consisting of a straight or branched chain of carbon and hydrogen atoms, having at least one triple bond. Non-limiting examples of alkynyl groups include, but are not limited to, ethynyl (-C≡CH), 1-propynyl (-C≡C-CH3), 2-propynyl (-CH2-C≡CH), and 1,3-butyrynyl (-C≡CC≡CH). The alkynyl group may optionally be substituted with one or more substituents as described herein.
[0211] The term "cycloalkyl" refers to a fully saturated carbon ring that may exist as a monocyclic, bridged, or spirocyclic ring. Unless otherwise indicated, the carbon ring is typically a 3- to 10-membered ring; preferably a 3- to 6-membered ring. Non-limiting examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl (bicyclo[2.2.1]heptyl), bicyclo[2.2.2]octyl, adamantyl, etc. The cycloalkyl ring may be fused to an aryl, heteroaryl, or heterocycloalkyl ring, wherein the ring attached to the parent structure is a cycloalkyl ring, and non-limiting examples include indanyl, tetrahydronaphthyl, benzocycloheptyl, etc. The cycloalkyl ring may optionally be substituted with one or more substituents as described herein.
[0212] The term "cycloalkenyl" refers to a partially unsaturated carbon ring that can exist as a monocyclic, spirocyclic, or bridged ring. Unless otherwise indicated, the cycloalkenyl group is C10. 3-12 Cycloalkenyl, preferably C 3-10 Cycloalkenyl groups, with C being a further preferred option. 3-7 Cycloalkenyl groups. Examples of cycloalkenyl groups include, but are not limited to, cyclopentenyl, cycloheptenyl, and cyclooctenyl. The cycloalkenyl group may optionally be substituted with one or more substituents as described herein.
[0213] The cycloalkenyl ring may be fused to an aryl, heteroaryl, or heterocyclic alkyl ring, wherein the ring connected to the parent structure is cycloalkenyl, and non-limiting examples include 1H indenyl, octahydronaphthyl, etc.
[0214] The term "heterocyclic group" refers to a non-aromatic ring that is fully saturated or partially unsaturated (but not fully unsaturated) and can exist as a monocyclic, bridged, fused, or spirocyclic ring. Unless otherwise indicated, the heterocycle is typically a 3-12, 3-10, 3-8, 3-6, 4-12, 4-10, 4-8, 4-6, 5-10, 5-8, 5-7, or 5-6 membered ring containing one to three heteroatoms independently selected from sulfur, silicon, phosphorus, oxygen, and / or nitrogen (preferably one or two heteroatoms), wherein the nitrogen atom is optionally quaternized, and the carbon, nitrogen, and sulfur heteroatoms may optionally be oxidized (i.e., C=O, NO, and S(O)). p (p is 1 or 2). Non-limiting examples of heterocyclic groups include, but are not limited to, ethylene oxide, tetrahydrofuranyl, dihydrofuranyl, 3,4-dihydropyranyl, 3,6-dihydropyranyl, pyrrolyl, N-methylpyrrolyl, dihydropyrrolyl, piperidinyl, piperazine, pyrazolyl, 4H-pyranyl, morpholinyl, thiomorpholinyl, tetrahydrothiophene, 2-oxa-7-azaspiro[3.5]nonyl, 2-oxa-6-azaspiro[3.3]heptyl, The heterocyclic ring may be fused to an aryl, heteroaryl, or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclic ring. It should be understood that the fused system formed after fusion falls within the scope of "heterocyclic group" as defined in this disclosure. The heterocyclic group may optionally be substituted by one or more substituents as described herein.
[0215] The term "heterocyclic alkyl" refers to a fully saturated cyclic group that can exist as a monocyclic, bridged, fused, or spirocyclic ring. Unless otherwise indicated, the heterocyclic alkyl group is typically a 3-12, 3-10, 3-8, 3-6, 4-12, 4-10, 4-8, 4-6, 5-10, 5-8, 5-7, or 5-6 membered ring containing one to three heteroatoms independently selected from sulfur, oxygen, nitrogen, phosphorus, silicon, and / or boron, wherein the nitrogen atom is optionally quaternized, and the carbon, nitrogen, and sulfur heteroatoms may optionally be oxidized (i.e., C=O, NO, and S(O)). p(where p is 1 or 2). Examples of 3-membered heterocyclic alkyl groups include, but are not limited to, ethylene oxide, cyclothioethylene, and cycloazoethylene; non-limiting examples of 4-membered heterocyclic alkyl groups include, but are not limited to, acridine, oxadiazolyl, and thiobutylcycloyl; examples of 5-membered heterocyclic alkyl groups include, but are not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, imidazolyl, and tetrahydropyrazolyl; examples of 6-membered heterocyclic alkyl groups include, but are not limited to, piperidinyl, tetrahydropyranyl, tetrahydrothiaranyl, morpholinyl, piperazine, 1,4-thiaoxane, 1,4-dioxane, thiomorpholinyl, 1,3-dithiaalkyl, and 1,4-dithiaalkyl; and examples of 7-membered heterocyclic alkyl groups include, but are not limited to, azirheptanyl, oxeheptyl, and thioheptyl. The heterocyclic alkyl groups may optionally be substituted with one or more substituents as described herein.
[0216] The term "heterocyclic alkenyl" refers to a partially unsaturated (but not completely unsaturated) heteroaromatic ring that can exist as a monocyclic, bridged, fused, or spirocyclic ring. Unless otherwise indicated, the heterocyclic alkenyl is typically a 3-12-membered, 3-10-membered, 3-8-membered, 3-6-membered, 4-12-membered, 4-10-membered, 4-8-membered, 4-6-membered, 5-10-membered, 5-8-membered, 5-7-membered, or 5-6-membered ring containing one to three heteroatoms independently selected from sulfur, oxygen, nitrogen, phosphorus, silicon, and / or boron, wherein the nitrogen atom is optionally quaternized, and the carbon, nitrogen, and sulfur heteroatoms may optionally be oxidized (i.e., C=O, NO, and S(O)). p (where p is 1 or 2). Examples of heterocyclic alkenyl groups include, but are not limited to, dihydropyrrolyl, dihydropyrazolyl, dihydroimidazolyl, dihydrofuranyl, dihydrooxazolyl, dihydroisooxazolyl, dihydrothiophenyl, dihydrothiazolyl, dihydroisothiazolyl, dihydropyridyl, dihydropyrimidinyl, dihydropyrazinyl, dihydropyridazinyl, tetrahydropyridyl, tetrahydropyrimidinyl, tetrahydropyrazinyl, tetrahydropyridazinyl, dihydropyranyl, aza-heptenyl, diaza-heptenyl, oxo-heptenyl, aza-heptenadienyl, diaza-heptendiyl, oxo-heptendienyl. The heterocyclic alkenyl group may optionally be substituted with one or more substituents as described herein.
[0217] The term "aryl" refers to an aromatic cyclic group consisting of an all-carbon monocyclic or fused polycyclic structure having a conjugated π-electron system. For example, an aryl group may have 6-20 carbon atoms, 6-14 carbon atoms, 6-12 carbon atoms, or 6-10 carbon atoms. Non-limiting examples of aryl groups include, but are not limited to, phenyl, naphthyl, and anthraceneyl groups. The aryl group may optionally be substituted by one or more substituents as described herein.
[0218] The term "heteroaryl" refers to an aromatic cyclic group having a conjugated π-electron system, containing at least one ring atom selected from N, O, and S, with the remainder being carbon atoms, wherein the nitrogen atom is optionally quaternized. The heteroaryl can be a monocyclic, fused bicyclic, or fused tricyclic system, wherein each ring is aromatic. The heteroaryl typically has 5 to 14 ring atoms, 5 to 12 ring atoms, 5 to 10 ring atoms, 5 to 8 ring atoms, 5 to 7 ring atoms, or 5 to 6 membered ring atoms. Preferred heteroaryls are selected from a single 4 to 8-membered ring, especially a 5 to 6-membered ring, or multiple fused rings containing 5 to 14, especially 5 to 10, ring atoms. The heteroaryl can be attached to the rest of the molecule via heteroatoms or carbon atoms. Non-limiting examples of the heteroaryl group include, but are not limited to, pyrrole rings (including N-pyrrole rings, 2-pyrrole rings, and 3-pyrrole rings, etc.), pyrazole rings (including 2-pyrazole rings and 3-pyrazole rings, etc.), imidazole rings (including N-imidazole rings, 2-imidazole rings, 4-imidazole rings, and 5-imidazole rings, etc.), oxazole rings (including 2-oxazole rings, 4-oxazole rings, and 5-oxazole rings, etc.), triazole rings (1H-1,2,3-triazole rings, 2H-1,2,3-triazole rings, 1H-1,2,4-triazole rings, and 4H-1,2,4-triazole rings, etc.), tetrazolium rings, isoxazole rings (3-isooxazole rings, 4-isooxazole rings, and 5-isooxazole rings, etc.), and thiazole rings (including 2-thiazole rings, 4-thiazole rings, and 5-thiazole rings, etc.). The heteroaryl group may be substituted with one or more substituents as described herein. These substituents may include azole rings, furan rings (including 2-furan rings and 3-furan rings), thiophene rings (including 2-thiophene rings and 3-thiophene rings), pyridine rings (including 2-pyridine rings, 3-pyridine rings and 4-pyridine rings), pyridine-2(1H)-one rings, pyrazine rings, pyrimidine rings (including 2-pyrimidine rings and 4-pyrimidine rings), benzothiazole rings (including 5-benzothiazole rings), purine rings, benzimidazole rings (including 2-benzimidazole rings), benzoxazole rings, indole rings (including 5-indole rings), isoquinoline rings (including 1-isoquinoline rings and 5-isoquinoline rings), quinoxaline rings (including 2-quinoxaline rings and 5-quinoxaline rings), and quinoline rings (including 3-quinoline rings and 6-quinoline rings). The heteroaryl group may optionally be substituted with one or more substituents as described herein.
[0219] The term "spirocyclic" refers to a fully saturated or partially unsaturated polycyclic system in which two monocyclic rings share a single carbon atom (called a spiro atom), including carbon rings and heterocyclic rings. The polycyclic system can be bicyclic, tricyclic, or tetracyclic, etc. Unless otherwise indicated, the spirocyclic ring is 5 to 20 elements, preferably 6 to 14 elements, and more preferably 9 to 14 elements. When the spirocyclic ring is a heterocyclic ring, one or more ring atoms in the polycyclic ring are selected from N, O, and S(O). n P(O) n (where n is 0, 1, or 2) heteroatoms (preferably 1 or 2 heteroatoms), with the remaining ring atoms being carbon atoms. Non-limiting examples of spirocycles include wait.
[0220] The term "bridging ring" refers to a fully saturated or partially unsaturated polycyclic system consisting of two monocyclic rings sharing three or more atoms, including carbon rings and heterocyclic rings. The polycyclic system can be bicyclic, tricyclic, or tetracyclic, etc. Unless otherwise indicated, the bridging ring is 5-18 atoms, preferably 6-14 atoms, and more preferably 6-10 atoms. Based on the number of rings, it can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridging rings, preferably bicyclic or tricyclic, and more preferably bicyclic. When the bridging ring is a heterocyclic ring, one or more ring atoms in the polycyclic ring are selected from N, O, and S(O). n P(O) n (where n is 0, 1, or 2) heteroatoms (preferably 1 or 2 heteroatoms), with the remaining ring atoms being carbon atoms. Non-limiting examples of bridged cycloalkyl groups include: wait.
[0221] The term "fused ring" refers to a polycyclic compound formed by the fusion of two monocyclic rings sharing two atoms, including fully saturated, partially saturated, and aromatic compounds. The polycyclic system can be bicyclic, tricyclic, or tetracyclic, etc. Unless otherwise indicated, the fused ring is 5 to 20 atoms, preferably 6 to 18 atoms, more preferably 8 to 16 atoms, and even more preferably 9 to 14 atoms. Non-limiting examples of fused rings include, but are not limited to, naphthalene, anthracene, phenanthrene, etc. wait.
[0222] The term "treatment" means administering the compound or preparation described in this application to improve or eliminate a disease or one or more symptoms related to said disease, and includes:
[0223] (i) Suppress the disease or disease state, that is, curb its development;
[0224] (ii) Relieve the disease or disease state, even if the disease or disease state subsides.
[0225] The term "therapeutic effective amount" means the amount of the compound of this application used to treat (i) the specific disease, condition, or disorder described herein, (ii) reduce, improve, or eliminate one or more symptoms of the specific disease, condition, or disorder described herein, or (iii) prevent or delay the onset of one or more symptoms of the specific disease, condition, or disorder described herein. The amount of the compound of this application constituting a "therapeutic effective amount" varies depending on the compound, the disease state and its severity, the route of administration, and the age of the mammal to be treated, but may routinely be determined by a person skilled in the art based on their own knowledge and the present disclosure.
[0226] The term "pharmaceutical acceptable" refers to compounds, materials, compositions, and / or dosage forms that, within the bounds of reliable medical judgment, are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio.
[0227] As pharmaceutically acceptable salts, for example, metal salts, ammonium salts, salts formed with organic bases, salts formed with inorganic acids, salts formed with organic acids, and salts formed with basic or acidic amino acids may be mentioned.
[0228] The term "pharmaceutical composition" refers to a mixture of one or more compounds of this application or their salts with pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate the administration of the compounds of this application to an organism.
[0229] The term "pharmaceuticalally acceptable excipient" refers to excipients that do not cause significant irritation to the organism and do not impair the biological activity and properties of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc.
[0230] The word “comprise” or “include” and its English variants such as comprises or comprising should be understood in an open, non-exclusive sense, meaning “including but not limited to”.
[0231] Unless otherwise specified, singular terms encompass plural terms, and plural terms encompass singular terms. Unless otherwise specified, the words "an" or "a" mean "at least one" or "at least one".
[0232] The compounds and intermediates of this application may also exist in different tautomer forms, and all such forms are included within the scope of this application. The terms "tautomer" or "tautomer form" refer to structural isomers of different energies that can interconvert via low energy barriers. For example, proton tautomers (also known as proton transfer tautomers) include interconversions via proton transfer, such as keto-enol and imine-enamine isomerization, keto-enol tautomers, for example... A specific example of a proton tautomer is the imidazole moiety, in which the proton can migrate between the two ring nitrogens, for example... Valence tautomers include tautomers that undergo recombination through the rearrangement of some bonding electrons.
[0233] The compounds of this invention can exist in specific geometric or stereoisomeric forms. This invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)- enantiomers, (R)- and (S)- enantiomers, diastereomers, (D)- isomers, (L)- isomers, and racemic mixtures thereof, as well as other mixtures, such as mixtures enriched with enantiomers or diastereomers, all of which are within the scope of this invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are included within the scope of this invention.
[0234] Unless otherwise specified, use wedge-shaped solid line keys. and wedge-shaped dashed key The absolute configuration of the center of a solid is represented by a straight solid line key. and straight dashed key The relative configuration of the center of a solid.
[0235] Optically active (R)- and (S)- isomers, as well as D- and L- isomers, can be prepared by chiral synthesis, chiral reagents, or other conventional techniques. To obtain an enantiomer of a compound of the present invention, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the desired enantiomer in pure form. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a salt of the diastereomeric isomer is formed with a suitable optically active acid or base, followed by diastereomeric resolution using conventional methods known in the art, and then the pure enantiomer is recovered. Furthermore, the separation of enantiomers and diastereomeric isomers is typically accomplished by using chromatography employing a chiral stationary phase and optionally combined with chemical derivatization (e.g., from amines to carbamates).
[0236] This application also includes compounds of this application that are identical to those described herein, but with one or more atoms replaced by isotopes whose atomic weights or mass numbers differ from those commonly found in nature. Examples of isotopes that can be incorporated into compounds of this application include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as... 2 H, 3 H, 11 C 13 C 14 C 13 N、 15 N、 15 O、 17 O、 18 O、 31 P, 32 P, 35 S,18 F, 123 I, 125 I and 36 Cl, etc.
[0237] Certain isotope-labeled compounds of this application (e.g., using...) 3 H and 14 Those labeled with C can be used in the analysis of compound and / or substrate tissue distribution. Tritiumization (i.e. 3 H) and carbon-14 (i.e. 14 C) Isotopes are particularly preferred due to their ease of preparation and detectability. Positron-emitting isotopes, such as... 15 O、 13 N、 11 C and 18 F can be used in positron emission tomography (PET) studies to determine substrate occupancy. The isotopically labeled compounds of this application can typically be prepared by replacing the unlabeled reagent with an isotopically labeled reagent using a procedure similar to those disclosed in the schemes and / or examples below.
[0238] In addition, heavier isotopes (such as deuterium) are used. 2 H)) substitution can provide certain therapeutic advantages resulting from higher metabolic stability (e.g., increased in vivo half-life or reduced dose requirement), and may therefore be preferred in certain situations, where deuterium substitution can be partial or complete, with partial deuterium substitution referring to at least one hydrogen being replaced by at least one deuterium.
[0239] The compounds of this application may be asymmetric, for example, having one or more stereoisomers. Unless otherwise stated, all stereoisomers include, such as enantiomers and diastereomers. The compounds containing asymmetric carbon atoms of this application can be isolated in optically active pure form or in racemic form. The optically active pure form can be resolved from a racemic mixture or synthesized using chiral starting materials or chiral reagents.
[0240] The pharmaceutical compositions of this application can be prepared by combining the compounds of this application with suitable pharmaceutically acceptable excipients.
[0241] The compounds of this application can be prepared by a variety of synthetic methods known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthetic methods, and equivalent substitutions known to those skilled in the art. Preferred embodiments include, but are not limited to, the embodiments of this application.
[0242] The chemical reactions in the specific embodiments of this application are carried out in a suitable solvent, which must be suitable for the chemical changes and the reagents and materials required in this application. In order to obtain the compounds of this application, it is sometimes necessary for those skilled in the art to modify or select the synthesis steps or reaction process based on existing embodiments.
[0243] An important consideration in synthetic route planning in this field is the selection of appropriate protecting groups for reactive functional groups (such as amino groups in this application). For example, see Greene's Protective Groups in Organic Synthesis (4th Ed). Hoboken, New Jersey: John Wiley & Sons, Inc. All references cited in this application are incorporated herein by reference in their entirety.
[0244] In some embodiments, the compounds disclosed herein can be prepared by those skilled in the art of organic synthesis by referring to the following routes:
[0245] Route 1:
[0246] in,
[0247] R 1 R 3 R 4 R a R b R c The definitions of X, Y, L, m, n and ring A are as described in this application;
[0248] LG is a leaving group; for example, LG can be independently selected from -Cl and -Br.
[0249] R X Selected from halogens, such as R X Selected from -Cl and -Br.
[0250] Route 2:
[0251] in,
[0252] R 1 R 3 R 4 R a R b R c The definitions of X, Y, L, m, n and ring A are as described in this application;
[0253] LG is a leaving group; for example, LG can be independently selected from -Cl and -Br.
[0254] RX Selected from halogens, such as R X Selected from -Cl and -Br. Detailed Implementation
[0255] For clarity, the present invention is further illustrated by examples, but these examples are not intended to limit the scope of this application. It will be apparent to those skilled in the art that various changes and modifications can be made to specific embodiments of the invention without departing from the spirit and scope thereof. All reagents used in this application are commercially available and can be used without further purification.
[0256] The compounds of this application can be prepared by those skilled in the art of organic synthesis with reference to the routes or methods of the following embodiments. The resulting compounds can be characterized by known instruments or methods, including but not limited to mass spectrometry, nuclear magnetic resonance, etc.
[0257] This application uses the following abbreviations:
[0258] EA represents ethyl acetate; PE represents petroleum ether; MeOH represents methanol; NaCl represents sodium chloride; Na2SO4 represents sodium sulfate; Pd(dppf)2Cl2 represents (1,1'-bis(diphenylphosphino)ferrocene)palladium dichloride; Pd(Ph3P)2Cl2 represents bis(triphenylphosphine)palladium dichloride; t-BuXPhos Pd G3 represents methanesulfonic acid (2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium; Pd(Ph3P)4 represents tetra(triphenylphosphine)palladium; DCM represents dichloromethane; THF represents tetrahydrofuran; NaOH represents sodium hydroxide; LiAlH4 represents lithium aluminum hydride; TLC represents thin-layer chromatography; "h" represents hours; "min" represents minutes.
[0259] Preparation Example A-1
[0260] Step a:
[0261] 3-Bromo-5-chlorobenzaldehyde (5.39 g), 3-((tributyltinyl)methoxy)-ethylamine (8.94 g) and Molecular sieve (21.5 g) was reacted in dichloromethane (120 mL) under nitrogen protection at room temperature for 4 h. The reaction was stopped, filtered, and the filtrate was collected and concentrated under reduced pressure to obtain an imine intermediate.
[0262] Copper(II) trifluoromethanesulfonate (9.41 g) was added to hexafluoroisopropanol (80 mL) under nitrogen protection and stirred at room temperature. 2,6-Dimethylpyridine (3.11 g) was slowly added dropwise, and the reaction was carried out at room temperature for 1 h. An imine intermediate dispersed in dichloromethane (320 mL) was slowly added to the above reaction system, and the reaction was carried out at room temperature. After the reaction was complete, the reaction solution was poured into a saturated sodium bicarbonate solution (160 mL) and 10% ammonia solution (80 mL), stirred for 30 min, allowed to stand for separation, extracted with dichloromethane (100 mL * 3), and the organic phases were combined. The mixture was washed successively with saturated sodium bicarbonate solution (100 mL) and saturated sodium chloride solution (100 mL), and the organic phase was collected. The mixture was dried over anhydrous sodium sulfate, filtered, concentrated, and separated by silica gel column chromatography to obtain intermediate A-1a.
[0263] LC-MS: m / z = 275.76(M+H) +
[0264] Step b:
[0265] Intermediate A-1a (5g) was placed in dichloromethane (50mL) and cooled to 0°C in an ice bath. Triethylamine (3.66g) was slowly added first, followed by acryloyl chloride (2.46g). The ice bath was removed, and the mixture was heated to room temperature for 30 min. After the reaction was complete, water (50mL) was added to the reaction solution, and the mixture was stirred to quench the reaction. The mixture was then extracted and separated. The aqueous phase was back-extracted with dichloromethane (25mL*3), and the organic phases were combined. The mixture was then washed with water (25mL) and saturated sodium chloride solution (25mL), respectively. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by silica gel column chromatography to obtain intermediate A-1b.
[0266] LC-MS: m / z = 329.84 (M+H) +
[0267] Step c:
[0268] Intermediate A-1b (2.5 g), pinacol diboronate (3.84 g), Pd(dppf)₂Cl₂ (550 mg), and potassium acetate (2.23 g) were placed in 1,4-dioxane (50 mL) under nitrogen protection and heated to 90 °C for 6 h. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (100 mL) and water (50 mL) were added to the reaction solution. The mixture was stirred, and the aqueous phase was extracted with ethyl acetate (50 mL x 3). The organic phases were combined. The mixture was washed once with water (50 mL) and once with saturated sodium chloride solution (50 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by silica gel column chromatography to obtain intermediate A-1.
[0269] LC-MS: m / z = 378.08(M+H) +
[0270] Preparation Example B-1
[0271] Step a: Synthesis of intermediate B-1a
[0272] (R)-3-(3-bromo-5-chlorophenyl)morpholine (5g) was dispersed in dichloromethane (50mL), cooled to 0°C in an ice bath, triethylamine (3.66g) was slowly added first, followed by acryloyl chloride (2.46g), the ice bath was removed, and the mixture was heated to room temperature and reacted for 30 min.
[0273] After the reaction was complete, water (50 mL) was added to the reaction solution, and the mixture was stirred to quench the reaction. The solution was then extracted and separated. The aqueous phase was back-extracted with dichloromethane (25 mL * 3), and the organic phases were combined. The solution was then washed with water (25 mL) and saturated sodium chloride solution (25 mL), and the organic phase was collected. The solution was dried over anhydrous sodium sulfate, filtered, concentrated, and separated by silica gel column chromatography to obtain intermediate B-1a.
[0274] LC-MS: m / z = 329.84 (M+H) +
[0275] Step b: Synthesis of intermediate B-1
[0276] Intermediate B-1a (2.5 g), pinacol diboronic acid ester (3.84 g), Pd(dppf)2Cl2 (550 mg), and potassium acetate (2.23 g) were dispersed in 1,4-dioxane (50 mL), purged with nitrogen for protection, heated to 90 °C, and reacted for 6 h.
[0277] After the reaction was complete, the mixture was cooled to room temperature. Then, ethyl acetate (100 mL) and water (50 mL) were added to the reaction solution and stirred. The mixture was extracted and separated. The aqueous phase was extracted with ethyl acetate (50 mL * 3), and the organic phases were combined. The mixture was washed once with water (50 mL) and once with saturated sodium chloride solution (50 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by silica gel column chromatography (PE:EA = 1:1) to obtain intermediate B-1.
[0278] LC-MS: m / z = 378.08(M+H) +
[0279] Example 1: Preparation of Compound 1
[0280] Step 1:
[0281] Methyl 3-amino-5-chlorobenzoate (3 g), 2-bromo-4-aminopyrimidine (5.62 g), t-BuXPhos Pd G3 (1.28 g), and potassium tert-butoxide (3.63 g) were dispersed in 1,4-dioxane (120 mL), and the mixture was purged under nitrogen protection and heated to 75 °C for 1 h. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (100 mL) and water (50 mL) were added to the reaction solution. The mixture was stirred, and the aqueous phase was extracted with ethyl acetate (50 mL x 3). The organic phases were combined. The mixture was washed once with water (50 mL) and once with saturated sodium chloride solution (50 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by silica gel column chromatography to obtain intermediate 1a.
[0282] LC-MS: m / z = 278.87(M+H) +
[0283] Step 2:
[0284] Intermediate 1a (2.57 g) was dispersed in tetrahydrofuran (128 mL), cooled to 0°C in an ice bath, and then 1 M LiAlH4 tetrahydrofuran solution (11 mL) was slowly added. After the addition was complete, the mixture was heated to room temperature and reacted for 30 min. After the reaction was complete, the mixture was cooled to 0°C again in an ice bath, and then 1 mL of water was slowly added to the reaction solution, followed by 1 mL of 15% NaOH aqueous solution, and then 3 mL of water. The mixture was heated to room temperature and stirred for 15 min. Finally, 10 g of anhydrous magnesium sulfate was added and stirred for 15 min. The mixture was filtered, concentrated, and separated by silica gel column chromatography to obtain intermediate 1b.
[0285] LC-MS: m / z = 250.89(M+H) +
[0286] Step 3:
[0287] Intermediate 1b (1.33 g) was dispersed in dichloromethane (66 mL), and activated manganese dioxide (2.66 g) was slowly added. The reaction was carried out at room temperature for 30 min. After the reaction was completed, the reaction solution was filtered, and the filter cake was washed with dichloromethane (20 mL * 2). The filtrate was concentrated under reduced pressure, and intermediate 1c was obtained by silica gel column chromatography.
[0288] LC-MS: m / z = 248.88(M+H) +
[0289] Step 4:
[0290] Intermediate 1c (1.0 g), 3-((tributyltinyl)methoxy)-ethylamine (1.46 g) and Molecular sieve (3.69 g) was dispersed in dichloromethane (80 mL) under nitrogen protection and reacted at room temperature for 4 h. After the reaction was stopped, the mixture was filtered, the filtrate was collected and concentrated under reduced pressure to obtain an imine intermediate for later use.
[0291] Copper(II) trifluoromethanesulfonate (1.54 g) was dispersed in hexafluoroisopropanol (25 mL) under nitrogen protection and stirred at room temperature. 2,6-Dimethylpyridine (0.51 g) was slowly added dropwise, and the reaction was carried out at room temperature for 1 h. The imine intermediate, dispersed in dichloromethane (100 mL), was slowly added to the above reaction system, and the reaction was carried out overnight at room temperature. After the reaction was complete, the reaction solution was poured into saturated sodium bicarbonate solution (50 mL) and 10% ammonia solution (25 mL), stirred for 30 min, allowed to stand for separation, and extracted with dichloromethane (50 mL * 3). The organic phases were combined, washed successively with saturated sodium bicarbonate solution (50 mL) and saturated sodium chloride solution (50 mL), and the organic phase was collected. The solution was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The intermediate 1d was obtained by silica gel column chromatography.
[0292] LC-MS: m / z = 305.94 (M+H) +
[0293] Step 5:
[0294] Intermediate 1d (356 mg) was dispersed in dichloromethane (35 mL), and triethylamine (235 mg) was slowly added. The mixture was then cooled to 0 °C in an ice bath. Acryloyl chloride (105 mg) was then slowly added, and the mixture was reacted in an ice bath for 30 min. After the reaction was complete, the reaction solution was concentrated under reduced pressure to obtain a crude product. The crude product was purified by preparative liquid chromatography (YMC AQ C18, mobile phase: A: 0.1% acetic acid, B: acetonitrile; gradient: 5%-35% B 0-60 min) to obtain compound 1.
[0295] LC-MS: m / z = 360.01(M+H) +
[0296] 1 H NMR (500MHz, DMSO-d) 6 )δ9.17(s,1H),7.85(d,J=5.8Hz,2H),7.18(s,1H),6.86(s,1H),6.64(s,1H),6.57(s,1H),6.21(dd,J=16.8,2.4Hz,1H),5.9 4(d,J=5.6Hz,1H),5.75(s,1H),5.32(t,J=4.6Hz,1H),4.36(d,J=11.9Hz,1H),3.86(s,1H),3.76(s,1H),3.51-3.44(m,1H).
[0297] Step 6:
[0298] Compound 1 was subjected to preparative liquid chromatography (YMC SA 10μm 30*250 column; 0.1% diethylamine ethanol-n-hexane (10%-60% / 0-40min gradient elution) to obtain compound 1A (Rt 18.3min) and compound 1B (Rt 21.6min).
[0299] Compound 1A: LC-MS: m / z = 360.01 (M+H) +
[0300] Compound 1B: LC-MS: m / z = 360.01 (M+H) +
[0301] Example 2: Preparation of Compound 2
[0302] Step 1:
[0303] 2,4-Dichloropyrimidine (500 mg), 2-(4,4,5,5-tetramethyl-1,3,2-dioxoborhexacyclopentan-2-yl)-1H-indole (979 mg), Pd(Ph3P)2Cl2 (471 mg), and potassium phosphate (2.14 g) were dispersed in 1,4-dioxane (20 mL) and water (4 mL). The mixture was placed under nitrogen protection and heated to 90 °C for 1 h. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (50 mL) and water (25 mL) were added to the reaction solution. The mixture was stirred, and the aqueous phase was extracted with ethyl acetate (25 mL x 3). The organic phases were combined. The mixture was washed once with water (25 mL) and once with saturated sodium chloride solution (25 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Intermediate 2a was obtained by silica gel column chromatography.
[0304] LC-MS: m / z = 229.90(M+H) +
[0305] Step 2:
[0306] Intermediate 2a (67 mg), intermediate A-1 (110 mg), Pd(Ph3P)4 (70 mg), and potassium phosphate (191 mg) were dispersed in 1,4-dioxane (8 mL) and water (1.6 mL), under nitrogen protection, and heated to 90 °C for 1 h. After the reaction was complete, the mixture was cooled to room temperature, and then ethyl acetate (20 mL) and water (20 mL) were added to the reaction solution. The mixture was stirred, extracted, and separated. The aqueous phase was extracted with ethyl acetate (15 mL * 3), and the organic phases were combined. The organic phase was washed once with water (15 mL) and once with saturated sodium chloride solution (15 mL). The organic phase was collected, dried with anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative liquid chromatography (YMC AQ C18, mobile phase: A: 0.1% acetic acid, B: acetonitrile; gradient: 20% B 0-5 min, 20%-55% B 5-10 min, 55%-85% B 10-70 min) to obtain compound 2.
[0307] LC-MS: m / z = 445.14 (M+H) +
[0308] 1 H NMR (500MHz, DMSO-d) 6 )δ11.98(d,J=2.3Hz,1H),8.91(d,J=5.3Hz,1H),8.74(s,1H),8.49(s,1H),7.99(d,J=5.3Hz,1H ),7.67(d,J=8.1Hz,1H),7.59(d,J=8.2Hz,2H),7.53(s,1H),7.26(t,J=8.2Hz,1H),7.09(t,J=6 .9Hz,1H),6.91(dd,J=16.6,10.2Hz,1H),6.27(d,J=18.9Hz,1H),5.80(d,J=12.8Hz,1H),5.65( s,1H),4.53(d,J=12.1Hz,1H),3.91(d,J=7.8Hz,1H),3.85(d,J=11.3Hz,1H),3.58-3.51(m,1H).
[0309] Step 3:
[0310] Compound 2 was subjected to preparative liquid chromatography using a YMC Amylose-SA (10 μm 30*250) column and eluted with an ethanol-n-hexane gradient (10%-90% / 0-40 min) to give compound 2A (Rt 17.2 min) and compound 2B (Rt 20.3 min).
[0311] Compound 2A: LC-MS: m / z = 445.01 (M+H) +
[0312] Compound 2B: LC-MS: m / z = 445.00 (M+H) +
[0313] Example 3: Preparation of Compound 3
[0314] Step 1:
[0315] 2,4-Dichloropyrimidine (500 mg), 5-(4,4,5,5-tetramethyl-1,3,2-dioxoborhexacyclopentan-2-yl)-1H-pyrazole (977 mg), Pd(Ph3P)2Cl2 (471 mg), and potassium phosphate (2.14 g) were dispersed in 1,4-dioxane (20 mL) and water (4 mL). The mixture was placed under nitrogen protection and heated to 90 °C for 1 h. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (50 mL) and water (25 mL) were added to the reaction solution. The mixture was stirred, and the aqueous phase was extracted with ethyl acetate (25 mL x 3). The organic phases were combined. The mixture was washed once with water (25 mL) and once with saturated sodium chloride solution (25 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Intermediate 3a was obtained by silica gel column chromatography.
[0316] LC-MS: m / z = 180.88(M+H) +
[0317] Step 2:
[0318] Intermediate 3a (52 mg), intermediate A-1 (110 mg), Pd(Ph3P)4 (70 mg), and potassium phosphate (191 mg) were dispersed in 1,4-dioxane (8 mL) and water (1.6 mL), under nitrogen protection, and heated to 90 °C for 1 h. After the reaction was complete, the mixture was cooled to room temperature, and then ethyl acetate (20 mL) and water (20 mL) were added to the reaction solution. The mixture was stirred, extracted, and separated. The aqueous phase was extracted with ethyl acetate (15 mL * 3), and the organic phases were combined. The organic phase was washed once with water (15 mL) and once with saturated sodium chloride solution (15 mL). The organic phase was collected, dried with anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative liquid chromatography (YMC AQ C18, mobile phase: A: 0.1% acetic acid, B: acetonitrile; gradient: 10% B 0-5 min, 10%-35% B 5-10 min, 35%-65% B 10-70 min) to obtain compound 3.
[0319] LC-MS: m / z = 396.00 (M+H) +
[0320] 1H NMR (500MHz, DMSO-d) 6 )δ8.96(d,J=5.2Hz,1H),8.78(d,J=2.7Hz,1H),8.30(s,1H),8.22(s,1H),8.09(d, J=5.2Hz,1H),7.90(s,1H),7.60(s,1H),6.91(dd,J=16.5,10.5Hz,1H),6.68-6.61 (m,1H),6.26(dd,J=16.6,2.3Hz,1H),5.79(d,J=11.1Hz,1H),5.62(s,1H),4.54(d ,J=12.2Hz,1H),3.90(d,J=9.9Hz,1H),3.84(d,J=10.8Hz,1H),3.58-3.50(m,1H).
[0321] Example 4: Preparation of Compound 4
[0322] Step 1: Synthesis of intermediate 4a
[0323] 2,4-Dichloropyrimidine (300 mg), 2-cyclopropylethylamine (257.2 mg), and N,N-diisopropylethylamine (521 mg) were dispersed in tetrahydrofuran (15 mL) and stirred for 1 h at room temperature.
[0324] After the reaction was complete, the mixture was cooled to room temperature. Then, ethyl acetate (50 mL) and water (25 mL) were added to the reaction solution and stirred. The mixture was extracted and separated. The aqueous phase was extracted with ethyl acetate (25 mL * 3), and the organic phases were combined. The mixture was washed once with water (25 mL) and once with saturated sodium chloride solution (25 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was separated by column chromatography to obtain intermediate 4a.
[0325] LC-MS: m / z = 197.93(M+H) +
[0326] Step 2: Synthesis of Compound 4
[0327] Intermediate 4a (58 mg), intermediate A-1 (110 mg), Pd(Ph3P)4 (70 mg), and potassium phosphate (191 mg) were dispersed in 1,4-dioxane (8 mL) and water (1.6 mL), under nitrogen protection, and the mixture was heated to 90 °C and reacted for 1 h.
[0328] After the reaction was complete, the mixture was cooled to room temperature. Ethyl acetate (20 mL) and water (20 mL) were then added to the reaction solution and stirred. The mixture was extracted and separated. The aqueous phase was extracted with ethyl acetate (15 mL x 3), and the organic phases were combined. The mixture was washed once with water (15 mL) and once with saturated sodium chloride solution (15 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative liquid chromatography (YMC TA C18 10 μm 30 x 250 column; acetonitrile-0.1% acetic acid aqueous solution (20%-70% / 0-45 min gradient elution) to obtain compound 4.
[0329] LC-MS: m / z = 413.10(M+H) +
[0330] 1 H NMR (500MHz, CDCl3) δ8.42-8.21(m,3H),7.70-7.64(m,1H),7.55(t,J=6.7Hz,1H),7.51-7.4 4(m,2H),6.58(dd,J=16.8,10.5Hz,1H),6.41(d,J=16.8Hz,1H),6.26(d,J=6.0Hz,1H),5.77( d,J=12.5Hz,1H),5.18(s,1H),4.53(d,J=12.2Hz,1H),3.97(d,J=15.4Hz,1H),3.89(d,J=12 .4Hz,1H),3.61(t,J=11.7Hz,1H),3.47(s,2H),0.51(d,J=9.6Hz,2H),0.13(d,J=4.9Hz,2H).
[0331] Examples 5-14: Synthesis of compounds 5-14
[0332] Compound 5-14 was obtained using intermediate A-1 or intermediate B-1, following the preparation method of Example 4.
[0333] Example 15: Preparation of Compound 15
[0334] Step 1: Synthesis of intermediate 15a
[0335] (R)-3-(3-bromo-5-chlorophenyl)morpholine (200 mg), 2,6-diaminopyridine (158 mg), t-BuXPhos Pd G3 (115 mg), and potassium tert-butoxide (243 mg) were dispersed in 1,4-dioxane (10 mL), nitrogen gas was purged, the temperature was raised to 90 °C, and the mixture was stirred for 1 h.
[0336] After the reaction was complete, the mixture was cooled to room temperature. Ethyl acetate (50 mL) and water (25 mL) were then added to the reaction solution, and the mixture was stirred. The aqueous phase was extracted with ethyl acetate (25 mL x 3), and the organic phases were combined. The mixture was washed once with water (25 mL) and once with saturated sodium chloride solution (25 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Intermediate 15a was obtained by column chromatography (eluent: DCM:MeOH).
[0337] LC-MS: m / z = 304.97 (M+H) +
[0338] Step 2: Synthesis of Compound 15
[0339] Intermediate 15a (100 mg), acryloyl chloride (45 mg), and N,N-diisopropylethylamine (85 mg) were dispersed in dichloromethane (10 mL) and reacted for 1 h under ice bath conditions.
[0340] After the reaction was complete, the temperature was raised to room temperature, and then dichloromethane (20 mL) and water (20 mL) were added to the reaction solution. The mixture was stirred, extracted, and separated. The aqueous phase was extracted with dichloromethane (15 mL * 3), and the organic phases were combined. The mixture was washed once with water (15 mL) and once with saturated sodium chloride solution (15 mL). The organic phase was collected, dried with anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative liquid chromatography (YMC TA C18 10 μm 30 * 250 column; acetonitrile-0.1% acetic acid aqueous solution (acetonitrile 10%-60% / 0-60 min gradient elution)) to obtain compound 15 (Rt 20.3 min).
[0341] LC-MS: m / z = 359.07 (M+H) +
[0342] 1H NMR (500MHz, DMSO-d6) δ8.87(s,1H),7.83(s,1H),7.58(s,1H),7.20(t,J=7. 9Hz,1H),6.83(s,1H),6.22(dd,J=16.8,2.4Hz,1H),5.96(d,J=7.6Hz,1H),5. 88(d,J=7.9Hz,1H),5.74(d,J=10.4Hz,1H),5.67(s,1H),5.48(s,1H),4.38(d ,J=12.1Hz,1H),3.86(d,J=11.1Hz,1H),3.75(s,1H),3.48(t,J=11.6Hz,1H).
[0343] Example 16: Synthesis of compounds 16-36
[0344] Referring to the preparation method of Example 15, wherein some compounds, including those in Examples 30, 32, 33, and 36, used racemic 3-(3-bromo-5-chlorophenyl)morpholine, compounds 16-36 were obtained.
[0345] Example 37: Preparation of compound 37
[0346] Step 1: Synthesis of intermediate 37a
[0347] 2,4-Dichloropyrimidine (303 mg), 2-pyridineboronic acid (250 mg), Pd(Ph3P)4 (470 mg), and potassium phosphate (1.29 g) were dispersed in 1,4-dioxane (15 mL) and water (3 mL), and the mixture was purged under nitrogen protection and heated to 90 °C for 1 h.
[0348] After the reaction was complete, the mixture was cooled to room temperature. Then, ethyl acetate (50 mL) and water (25 mL) were added to the reaction solution and stirred. The mixture was extracted and separated. The aqueous phase was extracted with ethyl acetate (25 mL * 3), and the organic phases were combined. The mixture was washed once with water (25 mL) and once with saturated sodium chloride solution (25 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The intermediate 37a was obtained by silica gel column chromatography (eluent: PE:EA).
[0349] LC-MS: m / z = 192.03(M+H) +
[0350] Step 2: Synthesis of Compound 37
[0351] Intermediate 37a (56 mg), intermediate B-1 (110 mg), Pd(Ph3P)4 (70 mg), and potassium phosphate (191 mg) were dispersed in 1,4-dioxane (8 mL) and water (1.6 mL), under nitrogen protection, and the mixture was heated to 90 °C and reacted for 1 h.
[0352] After the reaction was complete, the mixture was cooled to room temperature. Then, ethyl acetate (20 mL) and water (20 mL) were added to the reaction solution and stirred. The mixture was extracted and separated. The aqueous phase was extracted with ethyl acetate (15 mL * 3), and the organic phases were combined. The mixture was washed once with water (15 mL) and once with saturated sodium chloride solution (15 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative liquid chromatography (YMC TA C18 10 μm 30 * 250 column; acetonitrile-0.1% acetic acid aqueous solution (30%-90% / 0-60 min gradient elution) to obtain compound 37 (Rt 29.2 min).
[0353] LC-MS: m / z = 407.04 (M+H) +
[0354] 1 ¹H-NMR (500MHz, CDCl₃), δ: 8.93 (d, 1H), 8.74 (d, 1H), 8.65 (d, 1H), 8.58 (br, 1H), 8.51 (s, 1H), 8.29 (d, 1H), 7.92 (t, 1H), 7.71–7.38 (m, 2H), 6.74–6.37 (m, 2H), 6.22–4.88 (m, 2H), 4.58 (d, 1H), 4.25–3.01 (m, 5H). Example 38: Synthesis of compounds 38-40, 44-47, and 56.
[0355] Compounds 38-40, 44-47, and 56 were obtained by referring to the preparation method of Example 37.
[0356] Example 41: Preparation of compound 41
[0357] Step 1: Synthesis of intermediate 41a
[0358] 2,4-Dichloropyrimidine (303 mg), 1-Boc-pyrrole-2-boronic acid (644 mg), Pd(Ph3P)4 (470 mg), and potassium phosphate (1.29 g) were dispersed in 1,4-dioxane (15 mL) and water (3 mL), under nitrogen protection, and the mixture was heated to 90 °C and reacted for 1 h.
[0359] After the reaction was complete, the mixture was cooled to room temperature. Then, ethyl acetate (50 mL) and water (25 mL) were added to the reaction solution and stirred. The mixture was extracted and separated. The aqueous phase was extracted with ethyl acetate (25 mL * 3), and the organic phases were combined. The mixture was washed once with water (25 mL) and once with saturated sodium chloride solution (25 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The intermediate 41a was obtained by silica gel column chromatography (eluent: PE:EA).
[0360] LC-MS: m / z = 279.90 (M+H) +
[0361] Step 2: Synthesis of intermediate 41b
[0362] Intermediate 41a (384 mg) and trifluoroacetic acid (3 mL) were dispersed in dichloromethane (10 mL), and the mixture was stirred at room temperature for 1 h under nitrogen protection.
[0363] After the reaction was complete, ethyl acetate (50 mL) and saturated sodium bicarbonate solution (30 mL) were added to the reaction solution and stirred. The mixture was extracted and separated. The aqueous phase was extracted with ethyl acetate (25 mL * 3), and the organic phases were combined. The mixture was washed once with water (25 mL) and once with saturated sodium chloride solution (25 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The intermediate 41b was separated by silica gel column chromatography (eluent: PE:EA).
[0364] LC-MS: m / z = 180.04(M+H) +
[0365] Step 3: Synthesis of Compound 41
[0366] Intermediate 41b (52 mg), intermediate B-1 (110 mg), Pd(Ph3P)4 (70 mg), and potassium phosphate (191 mg) were dispersed in 1,4-dioxane (8 mL) and water (1.6 mL), under nitrogen protection, and the mixture was heated to 90 °C and reacted for 1 h.
[0367] After the reaction was complete, the mixture was cooled to room temperature. Then, ethyl acetate (20 mL) and water (20 mL) were added to the reaction solution and stirred. The mixture was extracted and separated. The aqueous phase was extracted with ethyl acetate (15 mL * 3), and the organic phases were combined. The mixture was washed once with water (15 mL) and once with saturated sodium chloride solution (15 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative liquid chromatography (YMC TA C18 10 μm 30 * 250 column; acetonitrile-0.1% formic acid aqueous solution (10%-60% / 0-60 min gradient elution) to obtain compound 41 (Rt 25.2 min).
[0368] LC-MS: m / z = 395.08 (M+H) +
[0369] 1 H NMR(500MHz,DMSO-d6)δ11.97(s,1H),8.72(d,J=5.5Hz,1H),8.67(s,1H),8.44(s ,1H),7.65(d,J=5.5Hz,1H),7.53(s,1H),7.13(d,J=11.1Hz,2H),6.89(dd,J=16. 8,10.2Hz,1H),6.30-6.22(m,2H),5.78(d,J=13.0Hz,1H),5.62(s,1H),4.51(d,J =12.2Hz,1H),3.90(d,J=15.6Hz,1H),3.83(d,J=11.0Hz,1H),3.58-3.50(m,1H).
[0370] Example 42: Synthesis of compounds 42, 43, 48–55, 57
[0371] Compounds 42, 43, 48–55, and 57 were obtained by referring to the preparation method of Example 41.
[0372] Example 58: Preparation of compound 58
[0373] Step 1: Synthesis of intermediate 58a
[0374] 2,6-Dichloro-4-aminopyrimidine (500 mg), indole-2-boronic acid (963 mg), Pd(Ph3P)4 (704 mg), and potassium phosphate (1.94 g) were dispersed in 1,4-dioxane (25 mL) and water (5 mL), under nitrogen protection, and the mixture was heated to 90 °C and reacted for 1 h.
[0375] After the reaction was complete, the mixture was cooled to room temperature. Then, ethyl acetate (80 mL) and water (40 mL) were added to the reaction solution and stirred. The mixture was extracted and separated. The aqueous phase was extracted with ethyl acetate (40 mL * 3), and the organic phases were combined. The mixture was washed once with water (50 mL) and once with saturated sodium chloride solution (50 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The intermediate 58a was obtained by silica gel column chromatography (eluent: PE:EA).
[0376] LC-MS: m / z = 244.88(M+H) +
[0377] Step 2: Synthesis of Compound 58
[0378] Intermediate 58a (94 mg), intermediate B-1 (218 mg), Pd(Ph3P)4 (89 mg), and potassium phosphate (245 mg) were dispersed in 1,4-dioxane (8 mL) and water (1.6 mL), under nitrogen protection, and the mixture was heated to 90 °C and reacted for 1 h.
[0379] After the reaction was complete, the mixture was cooled to room temperature. Then, ethyl acetate (20 mL) and water (20 mL) were added to the reaction solution and stirred. The mixture was extracted and separated. The aqueous phase was extracted with ethyl acetate (15 mL * 3), and the organic phases were combined. The mixture was washed once with water (15 mL) and once with saturated sodium chloride solution (15 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative liquid chromatography (YMC TA C18 10 μm 30 * 250 column; acetonitrile-0.1% trifluoroacetic acid aqueous solution (40%-80% / 0-60 min gradient elution) to obtain compound 58 (Rt 29 min).
[0380] LC-MS: m / z = 460.04 (M+H) +
[0381] Example 59: Synthesis of compounds 59-62
[0382] Referring to the preparation method of Example 58, some compounds, including those from Example 60, were prepared by replacing 2,6-dichloro-4-aminopyrimidine with 2-amino-4,6-dichlorotriazine, resulting in compounds 59-62.
[0383] Example 63: Preparation of compound 63
[0384] Step 1: Synthesis of intermediate 63a
[0385] (R)-3-(3-bromo-5-chlorophenyl)morpholine (274 mg), zinc cyanide (235 mg), and tetra(triphenylphosphine)palladium (150 mg) were dispersed in N,N-dimethylformamide (10 mL), nitrogen gas was purged, the temperature was raised to 150 °C, and the mixture was stirred for 2 h.
[0386] After the reaction was complete, the mixture was cooled to room temperature. Ethyl acetate (50 mL) and water (25 mL) were then added to the reaction solution, and the mixture was stirred. The aqueous phase was extracted with ethyl acetate (25 mL x 3), and the organic phases were combined. The mixture was washed once with water (25 mL) and once with saturated sodium chloride solution (25 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Intermediate 63a was obtained by column chromatography (eluent: PE:EA).
[0387] LC-MS: m / z = 223.05(M+H) +
[0388] Step 2: Synthesis of intermediate 63b
[0389] Intermediate 63a (100 mg) and potassium hydroxide (600 mg) were dispersed in EtOH:H2O = 1:1 (10 mL), nitrogen gas was purged, the temperature was raised to 80 °C, and the mixture was stirred for 3 h.
[0390] After the reaction was complete, the mixture was allowed to cool naturally to room temperature. 10% dilute hydrochloric acid was added to adjust the pH to 7-8. The reaction solution was then concentrated under reduced pressure to remove water and ethanol, yielding crude intermediate 63b. This crude intermediate was not purified before proceeding to the next step of the reaction.
[0391] Step 3: Synthesis of intermediate 63c
[0392] The crude intermediate 63b (80 mg) and triethylamine (30 mg) were dispersed in tetrahydrofuran (5 mL), and after replacing the nitrogen gas, the temperature was lowered to 0 °C. Acryloyl chloride (54 mg) was slowly added dropwise, and the mixture was stirred at 0 °C for 1 h.
[0393] After the reaction was complete, the mixture was brought to room temperature. Ethyl acetate (50 mL) and water (25 mL) were then added to the reaction solution, and the mixture was stirred. The aqueous phase was extracted with ethyl acetate (25 mL x 3), and the organic phases were combined. The mixture was washed once with water (25 mL) and once with saturated sodium chloride solution (25 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Column chromatography (eluent: PE:EA) was used to separate intermediate 63c.
[0394] LC-MS: m / z = 296.06 (M+H) +
[0395] Step 4: Synthesis of intermediate 63d
[0396] Intermediate 63d (100 mg) was dispersed in tetrahydrofuran (5 mL), nitrogen gas was purged, the temperature was lowered to 0 °C, and thionyl chloride (200 mg) was slowly added dropwise. After the addition was complete, the temperature was naturally raised to room temperature and the mixture was stirred for 2 h.
[0397] After the reaction was complete, the reaction solution was directly concentrated under reduced pressure to remove tetrahydrofuran and thionyl chloride, and crude intermediate 63d was obtained without purification.
[0398] Step 5: Synthesis of intermediate 63e
[0399] 2-Amino-4-bromopyrimidine (60 mg) was dispersed in tetrahydrofuran (5 mL), and nitrogen gas was purged. The crude intermediate 63d was dispersed in tetrahydrofuran (1 mL) and slowly added dropwise to the reaction solution at room temperature. After the addition was complete, triethylamine (200 mg) was added, and the mixture was heated to 60 °C and stirred for 2 h.
[0400] After the reaction was complete and cooled to room temperature, ethyl acetate (50 mL) and water (25 mL) were added to the reaction solution and stirred. The mixture was extracted and separated. The aqueous phase was extracted with ethyl acetate (25 mL * 3), and the organic phases were combined. The mixture was washed once with water (25 mL) and once with saturated sodium chloride solution (25 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Column chromatography (eluent PE:EA) was used to separate intermediate 63e.
[0401] LC-MS: m / z = 451.01(M+H) +
[0402] Step 6: Synthesis of intermediate 63f
[0403] Intermediate 63e (50 mg) was dispersed in N,N-dimethylacetamide (2 mL), and 2,4-dimethoxyanisole (38 mg), cesium carbonate (120 mg), tris(dibenzylacetone)palladium (10 mg), and 1,1'-binaphthyl-2,2'-bisdiphenylphosphine (14 mg) were added. Nitrogen gas was used for protection, and the mixture was heated to 100 °C and stirred for 8 h.
[0404] After the reaction was complete and cooled to room temperature, ethyl acetate (5 mL) and water (3 mL) were added to the reaction solution and stirred. The mixture was extracted and separated. The aqueous phase was extracted with ethyl acetate (5 mL * 3), and the organic phases were combined. The mixture was washed once with water (5 mL) and once with saturated sodium chloride solution (5 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Column chromatography (eluent: PE:EA) was used to separate intermediate 63f.
[0405] LC-MS: m / z = 506.19 (M+H) +
[0406] Step 7: Synthesis of Compound 63
[0407] Intermediate 63f (80 mg) was dispersed in methanol (2 mL), and trifluoroacetic acid (100 mg) was added. The mixture was stirred at room temperature for 3 h under nitrogen protection.
[0408] After the reaction was complete, ethyl acetate (10 mL) and water (10 mL) were added to the reaction solution and stirred. The mixture was extracted and separated. The aqueous phase was extracted with ethyl acetate (10 mL * 3), and the organic phases were combined. The mixture was washed once with water (10 mL) and once with saturated sodium chloride solution (10 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative liquid chromatography (YMC AQ C18, specification 30 * 250 mm, 10 μm, mobile phase: A: 0.1% acetic acid, B: acetonitrile; gradient: 5% B 0-10 min, 5%-40% B 10-80 min) to obtain compound 63 (Rt 35 min).
[0409] LC-MS: m / z = 388.06 (M+H) +
[0410] Effect of Compound 1 on NRF2 Degradation in Cells
[0411] 1.1 Assay of NRF2 protein degradation activity in KYSE70 cells (in-cell Western blotting)
[0412] Take KYSE70 cells in good growth condition, wash with PBS, digest with trypsin, stop digestion with 10% FBS in 1640 complete medium, collect in centrifuge tubes, and adjust the cell density to 2.5 × 10⁻⁶ cells / cm³. 5 Cells were seeded at a concentration of 40 μL / well in 384-well plates and incubated overnight at 37°C. Compounds were added using a nanoparticle pipette to a final concentration of 1000 nM - 0.061 nM, with two replicates and a control. After culturing for 24 hours, the supernatant was discarded, and 40 μL of paraformaldehyde (manufacturer: Sangon Biotech) was added to each well, incubated at room temperature for 20 minutes. The supernatant was then discarded, and the cells were washed twice with 40 μL of PBS, followed by 40 μL of ice-cold methanol (manufacturer: Merck) to each well, incubated at room temperature for 10 minutes. Finally, the supernatant was discarded, and the cells were washed twice with 40 μL of TBST, followed by 40 μL of 2% PBS to each well. BSA-TBST blocking buffer, incubate at room temperature for 60 minutes; discard the supernatant, add 20 μL of a mixture of GAPDH mouse antibody (manufacturer: R&D) and NRF2 rabbit antibody (manufacturer: CST) prepared with blocking buffer to each well, incubate overnight at 4°C; discard the supernatant, add 40 μL of TBST to each well and wash twice, then add 20 μL of Anti-mouse IgG (H+L) (Dylight) prepared with blocking buffer to each well. TM 680 Conjugate) antibody and Anti-rabbit IgG (H+L) (Dylight) TM800 μL of 4×PEG Conjugate antibody mixture (manufacturer: CST) was incubated at room temperature in the dark for 45 minutes; the supernatant was discarded, and each well was washed twice with 40 μL of TBST, followed by one wash with 40 μL of PBS. The mixture was then incubated in Azure Sapphire. TM Detection was performed using a dual-mode multispectral laser imaging system (In-Cell WB-800nm, 680nm), four-parameter analysis was conducted, the dose-response curve was fitted, and DC was calculated. 50 and D max (%, maximum degradation rate). The results are shown in Table 1, where A represents DC. 50 Less than or equal to 50nM, +++ represents D max (%) greater than or equal to 50%.
[0413] Table 1. Effects of compounds on NRF2 degradation in cells.
[0414] Test Example 2: Liver Microsomal Stability Test
[0415] Liver microsomal incubation samples were prepared by incubating liver microsomal solution (0.5 mg / mL) in mixed PBS buffer (pH 7.4), along with the test compound and NADPH + MgCl2 solution at 37°C and 300 rpm for 1 hour. Samples prepared at 0 hours were prepared with mixed PBS buffer (pH 7.4), liver microsomal solution (0.5 mg / mL), and the test compound. After adding acetonitrile solution containing an internal standard, the samples underwent protein precipitation to prepare a supernatant, which was then diluted for LC / MS / MS analysis.
[0416] The results showed that the compounds of this application have good in vitro liver microsome stability; for example, some compounds of this application had a residual amount of >50% in human liver microsome solution after 60 min.
[0417] Experimental Example 3: Pharmacokinetic Study in Mice
[0418] ICR mice, weighing 18–22 g, were randomly divided into groups of 6 mice each after acclimatization for 3–5 days. The gavage group was administered the test compound solution by gavage at a dose of 10 mg / kg, while the intravenous injection group was administered the test compound solution by intravenous injection at a dose of 1 mg / kg.
[0419] Blood samples were collected at 15 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h for the gavage administration group and at 5 min, 15 min, 1 h, 2 h, 4 h, 8 h, and 24 h for the intravenous injection group. Blood was collected from the orbital cavity to prepare plasma samples for testing.
[0420] Take 30 μL of the plasma sample and standard curve sample, add acetonitrile solution containing internal standard, and obtain the supernatant after protein precipitation. Dilute the supernatant and use it for LC / MS / MS analysis. Pharmacokinetic parameters are fitted using a non-compartmental model.
[0421] The experimental results showed that the compounds of this application have good in vivo pharmacokinetic properties, such as AUC, t1 / 2, Cmax, and F. For example, in the gavage administration group, the AUC (0-8h) of some compounds of this application was >1500 ng*h / mL.
[0422] Experimental Example 4: Pharmacokinetic Study in Rats
[0423] SD rats, weighing 180–220 g, were randomly divided into groups of 3 rats each after acclimatization for 3–5 days. The test compound solution was administered by gavage at a dose of 10 mg / kg and by intravenous injection at a dose of 1 mg / kg.
[0424] Blood samples were collected at 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 10h, and 24h after oral administration; and at 0.083h, 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 10h, and 24h after intravenous administration. Plasma samples were prepared from the orbital rim.
[0425] 30 μL of the plasma sample and standard curve were taken, and acetonitrile solution containing internal standard was added. Protein precipitation was performed to obtain the supernatant, which was then diluted for LC / MS / MS analysis. Pharmacokinetic parameters were fitted using a non-compartmental model. Results are shown in Table 2.
[0426] Table 2
[0427] Effect of Experiment 5 on the subcutaneous xenograft tumor (KYSE70 cells) model in female B-NDG mice
[0428] The experimental results showed that the compound of this application has the effect of inhibiting tumor volume and weight.
[0429] The technical features of any of the above embodiments can be combined with the technical features of another embodiment without departing from the inventive concept of this application, and the resulting new technical solution still falls within the scope of this application.
[0430] These embodiments and examples are described to better explain the principles and applications of this application, thereby enabling those skilled in the art to understand the various embodiments and modifications of this application, but do not constitute any limitation on this application. The scope of this application should be defined by the claims and their equivalents.
Claims
Compound of formula (I), its stereoisomers, or pharmaceutically acceptable salts thereof, in, X is selected from -CH2-, -N(R) 2 -, -O-, or -S-; Each R 1 Each is independently selected from deuterium, halogens, -NH2, -OH, =O, -CN, -C(O)NH2, or optionally by one or more R 1a The following groups are substituted: C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl)2、-C(O)C 1-6 Alkyl group, -C(O)NHC 1-6 Alkyl, or -C(O)N(C 1-6 Alkyl)2; Or, two R atoms on the same carbon atom 1 Together with the carbon atoms they are attached to, they form optional groups of one or more R atoms. 1a Replacement C 3-6 cycloalkyl; R 2 Selected from H, or arbitrarily selected by one or more R 2a The following groups are substituted: C 1-6 Alkyl, -C(O)C 1-6 Alkyl, -C(O)C 3-6 Cycloalkyl, -S(O)C 1-6 Alkyl, -S(O)C 3-6 Cycloalkyl, -S(O)2C 1-6 Alkyl group, or -S(O)2C 3-6 cycloalkyl; R a R b and R c Each is independently selected from hydrogen, deuterium, halogens, and carbon. 1-6 Alkyl, or C 1-6 Halogenated alkyl groups; Y is selected from CH or N; Each R 3 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, or optionally influenced by one or more R. 3a Replace the following groups: C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -NH(C) 1-6 alkyl), or -N(C) 1-6 Alkyl)2; L is selected from the bond, -NH-, or -C(O)NH-; When L is selected from the bond, Ring A is selected from any one or more R 5 The following groups are substituted: C 6-10 Aryl, or 5-12 heteroaryl; R 4 Selected from one or more R 4a The following groups are substituted: C 6-10 Aryl, 5-12 membered heteroaryl, 9-12 membered heterocyclic, -NR 4c R 4d 、or -C(O)NR 4c R 4d ; Each R 5 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, or optionally influenced by one or more R. 5a The following groups are substituted: C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl)2、-C(O)OC 1-6 Alkyl, -C(O)C 1-6 Alkyl group, -C(O)NHC 1-6 Alkyl, or -C(O)N(C 1-6 Alkyl)2; When L is selected from -NH- or -C(O)NH- Ring A is selected from any one or more R 6 The following groups are substituted: C 6-10 Aryl, or 5-12 heteroaryl; R 4 It does not exist, or is selected from one or more Rs. 4b The following groups are substituted: C 6-10 Aryl, 5-12 membered heteroaryl, 4-12 membered heterocyclic, -NR 4c R 4d 、or -C(O)NR 4c R 4d ; Each R 6 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, -C(O)NH2, or optionally by one or more R 6a The following groups are substituted: C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl)2、-C(O)C 1-6 Alkyl, -C(O)OC 1-6 Alkyl group, -C(O)NHC 1-6 Alkyl, -C(O)N(C) 1-6 Alkyl)2、-NHC(O)C 1-6 Alkyl group, -S(O)2C 1-6 Alkyl group, -S(O)2NHC 1-6 Alkyl group, -S(O)2N(C) 1-6 alkyl)2、-NHS(O)2C 1-6 Alkyl, -NHC(O)OC 1-6 Alkyl group, -NHC(O)NHC 1-6 Alkyl, or -NHC(O)N(C 1-6 Alkyl)2; R 4c Each is independently selected from hydrogen, deuterium, or C. 1-6 alkyl; R 4d Each was independently selected from C 2-6 alkenyl, C 2-6 alkynyl group, -C 1-6 Alkylene-C(O)NHC 1-6 Alkyl, -C 1-6 Alkylene-C(O)N(C) 1-6 Alkyl)2, -C 1-6 Alkylene-C 3-12 cycloalkyl, -C 1-6 Alkylene-3-12-membered heterocyclic alkyl, -C 1-6 Alkylene-C 6-10 Aryl, -C 1-6 alkylene-5-12-membered heteroaryl, C 6-10 Aryl, or 5-12 heteroaryl; Each R 1a R 2a R 3a R 4a R 4b R 5a and R 6a Each is independently selected from deuterium, halogens, -NH2, -OH, =O, -CN, and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl)2、-C(O)C 1-6 Alkyl, -C(O)OC 1-6 Alkyl group, -C(O)NHC 1-6 Alkyl, -C(O)N(C) 1-6 Alkyl)2、-NHC(O)C 1-6 Alkyl group, -S(O)2C 1-6 Alkyl group, -S(O)2NHC 1-6 Alkyl group, -NHS(O)2C 1-6 Alkyl, -NHC(O)OC 1-6 Alkyl group, -NHC(O)NHC 1-6 Alkyl, or -NHC(O)N(C 1-6 Alkyl)2, C 3-6 Cycloalkyl or 3-6 membered heterocyclic groups; m is selected from 0, 1, 2, 3, 4, 5, or 6; n is selected from 0, 1, 2, 3 or 4. The compound of formula (I) as claimed in claim 1, its stereoisomers, or pharmaceutically acceptable salts thereof, wherein, X is selected from -O-; or, X is selected from -N(R) 2 )-; Optional, R 2 Selected from H, or arbitrarily selected by one or more R 2a The following groups are substituted: C 1-4 Alkyl, -C(O)C 1-4 Alkyl, -C(O)C 3-6 Cycloalkyl, -S(O)C 1-4 Alkyl, -S(O)C 3-6 Cycloalkyl, -S(O)2C 1-4 Alkyl group, or -S(O)2C 3-6 cycloalkyl; Or, R 2 Selected from H, methyl, ethyl, -C(O)CH3, -C(O)cyclopropane, -S(O)CH3, -S(O)cyclopropane, -S(O)2CH3, or -S(O)2cyclopropane; Optionally, each R 2a Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, and C. 1-4 Alkyl, deuterated C 1-4 Alkyl, Halogenated C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), or -N(C) 1-4 Alkyl)2. The compound of formula (I) as claimed in claim 1 or 2, its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein, Each R 1 Each is independently selected from deuterium, halogens, -NH2, -OH, =O, -CN, -C(O)NH2, or optionally by one or more R 1a The following groups are substituted: C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), -N(C) 1-4 Alkyl)2、-C(O)C 1-4 Alkyl group, -C(O)NHC 1-4 Alkyl, or -C(O)N(C 1-4 Alkyl)2; Or, two R atoms on the same carbon atom 1 Together with the carbon atoms they are attached to, they form optional groups of one or more R atoms. 1a Replacement C 3-4 cycloalkyl; Or, each R 1 Each is independently selected from deuterium, halogens, -NH2, -OH, =O, -CN, -C(O)NH2, or optionally by one or more R 1a The following groups are substituted: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl; Optionally, each R 1a Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, and C. 1-4 Alkyl, deuterated C 1-4 Alkyl, Halogenated C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), or -N(C) 1-4 Alkyl)2. The compound of formula (I) as claimed in any one of claims 1-3, its stereoisomers, or pharmaceutically acceptable salts thereof, wherein, R a R b and R c Each is independently selected from hydrogen, deuterium, halogens, and carbon. 1-4 Alkyl, or C 1-4 Halogenated alkyl groups; Or, R a R b and R c All are hydrogen; Optionally, of which, Y is selected from CH. The compound of formula (I) as claimed in any one of claims 1-4, its stereoisomers, or pharmaceutically acceptable salts thereof, wherein, Each R 3 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, or optionally influenced by one or more R. 3a Replace the following groups: C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), or -N(C) 1-4 Alkyl)2; Or, each R 3 Each is independently selected from deuterium, halogen, -NH2, -OH, -CN, -NO2, methyl, methoxy, methylthio, methylamino, dimethylamino, trifluoromethyl, trideuterated methyl, or hydroxymethyl; Or, each R 3 Each is independently selected from -F, -Cl, or -Br; Optionally, each R 3a Each is independently selected from deuterium, halogens, -NH2, -OH, =O, -CN, and C. 1-4 Alkyl, deuterated C 1-4 Alkyl, Halogenated C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), -N(C) 1-4 Alkyl)2, C 3-6 Cycloalkyl or 3-6 membered heterocyclic groups. The compound of formula (I) as claimed in any one of claims 1-5, its stereoisomers, or pharmaceutically acceptable salts thereof, wherein, When L is selected from the key, ring A is selected from any one or more R. 5 The following groups are substituted: C 6-10 Aryl, or 5-9 membered heteroaryl; Alternatively, when L is selected from the key, ring A is selected from any one or more R. 5 The following groups are substituted: phenyl, or 5-6 membered heteroaryl; When L is selected from the key, ring A is selected from any one or more R. 5 The following groups are substituted: phenyl, or containing 1-3 5-6 membered heteroaryl groups selected from N heteroatoms; Alternatively, when L is selected from the key, ring A is selected from any one or more R. 5 The following groups are substituted: containing 1-3 six-membered heteroaryl groups selected from N heteroatoms; Alternatively, when L is selected from the bond, ring A is selected from pyrimidinyl or 1,3,5-triazineyl; Alternatively, when L is selected from the key, ring A is selected from... Where "*" represents the end connected to L; optionally, each R 5 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, or optionally influenced by one or more R. 5a The following groups are substituted: C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), or -N(C) 1-4 Alkyl)2; Or, each R 5 Each is independently selected from one or more R options. 5a The following groups are substituted: -C(O)OC 1-4 Alkyl, -C(O)C 1-4 Alkyl group, -C(O)NHC 1-4 Alkyl, or -C(O)N(C 1-4 Alkyl)2; Optionally, each R 5a Each is independently selected from deuterium, halogens, -NH2, -OH, =O, -CN, and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 alkyl. The compound of formula (I) as claimed in any one of claims 1-6, its stereoisomers, or pharmaceutically acceptable salts thereof, wherein, When L is selected from the bond, R 4 Selected from one or more R 4a The following groups are substituted: C 6-10 Aryl, 5-6 nucleotide monocyclic heteroaryl, 8-12 nucleotide bicyclic heteroaryl, 9-12 nucleotide bicyclic heterocyclic, -NHR 4d 、or -C(O)NHR 4d ; Or, when L is selected from the key, R 4 Selected from one or more R 4a The following groups are substituted: 5-6 membered monocyclic heteroaryl groups containing 1-3 heteroatoms selected from N, O or S heteroatoms; 9-10 membered bicyclic heteroaryl groups containing 1-5 heteroatoms selected from N, O or S heteroatoms; or 9-10 membered bicyclic heterocyclic diaryl groups containing 1-5 heteroatoms selected from N, O or S heteroatoms. Or, when L is selected from the key, R 4 Selected from one or more R 4a The following groups are substituted: Or, when L is selected from the key, R 4 Selected from Or, when L is selected from the key, R 4 Selected from one or more R 4a The following groups are substituted: -NR 4c R 4d 、or -C(O)NR 4c R 4d ; Or, R 4 Selected from one or more R 4a The following groups are substituted: Or, when L is selected from the key, R 4 Selected from Optionally, each R 4a Each is independently selected from deuterium, -F, -Cl, -Br, -NH2, -OH, =O, -CN, methyl, ethyl, n-propyl, isopropyl, -CD3, -CF3, -CH2CF3, -OCH3, -CH2CH3, -C(O)OCH3, -C(O)OCH2CH3, -C(O)NHCH3, or -C(O)N(CH3)2; Or, each R 4a Each is independently selected from deuterium, -F, -Cl, -Br, -NH2, -OH, =O, -CN, methyl, -CF3, -CH2CF3, -OCH3, or -C(O)OCH3; Optional, R 4c Each is independently selected from hydrogen, deuterium, or C. 1-4 alkyl; Or, R 4c Each is independently selected from hydrogen, methyl, ethyl, n-propyl, or isopropyl; Optional, R 4d Each was independently selected from C 2-4 alkenyl, C 2-4 alkynyl group, -C 1-4 Alkylene-C(O)NH(C) 1-4 Alkyl), -C 1-4 Alkylene-C(O)N(C) 1-4 Alkyl)2, -C 1-4 Alkylene-C 3-6 cycloalkyl, -C 1-4 Alkylene-3-6-membered heterocyclic alkyl, -C 1-4 alkylene-phenyl, -C 1-4 Alkylene-5-6-membered heteroaryl, phenyl, or 5-6-membered heteroaryl; Or, R 4d Each was independently selected from C 2-4 alkenyl, C 2-4 alkynyl group, -C 1-4 Alkylene-C(O)NH(C) 1-4 Alkyl), -C 1-4 Alkylene-C 3-6 cycloalkyl, -C 1-4 Alkylene-3-6-membered heterocyclic alkyl, -C 1-4 Alkylene-phenyl, phenyl, or 5-6-membered heteroaryl; Or, each R 4d Each is independently selected from vinyl, propenyl, butenyl, ethynyl, propynyl, butynyl, -CH2C(O)NHCH3, -CH2C(O)NHCH2CH3, -CH2CH2C(O)NHCH3, -CH2CH2C(O)NHCH2CH3, -methylenecyclopropyl, -ethylcyclopropyl, -methylenecyclobutyl, -ethylcyclobutyl, -methylenecyclopentyl, -ethylcyclopentyl, -methylenetetrahydrofuranyl, -ethyltetrahydrofuranyl, -methylenetetrahydropyrrolyl, -ethyltetrahydropyrrolyl, -methylenetetrahydropyrrolyl, -ethyltetrahydropyrrolyl, -ethyltetrahydropyrrolyl, -methylenepiperidinyl, -ethylpiperidinyl, -methylenephenyl, -ethylphenyl, -methylenepyridinyl, -ethylpyridinyl, phenyl, or pyridine; Or, each R 4d Each independently selected The compound of formula (I) as claimed in any one of claims 1-7, its stereoisomers, or pharmaceutically acceptable salts thereof, wherein, When L is selected from -NH- or -C(O)NH-, ring A is selected from one or more R-. 6 The following groups are substituted: C 6-10 aryl, or 5-10 heteroaryl; or, when L is selected from -NH- or -C(O)NH-, ring A is selected from one or more R groups. 6 The following groups may be substituted: phenyl, naphthyl, 5-6 membered monocyclic heteroaryl containing 1-3 heteroatoms selected from N, O, or S, and 9-10 membered bicyclic heteroaryl containing 1-5 heteroatoms selected from N, O, or S. Alternatively, when L is selected from -NH- or -C(O)NH-, ring A is selected from any one or more R-. 6 The following groups are substituted: phenyl, pyridyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl. When L is selected from -NH- or -C(O)NH-, ring A is selected from one or more R-. 6 The following groups are substituted: Where "*" represents the end connected to L; Optionally, each R 6 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, -C(O)NH2, or optionally by one or more R 6a The following groups are substituted: C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), -N(C) 1-4 Alkyl)2、-C(O)C 1-4 Alkyl, -C(O)OC 1-4 Alkyl group, -C(O)NHC 1-4 Alkyl, -C(O)N(C) 1-4 Alkyl)2、-NHC(O)C 1-4 Alkyl group, -S(O)2C 1-4 Alkyl group, -S(O)2NHC 1-4 Alkyl group, -S(O)2N(C) 1-4 alkyl)2、-NHS(O)2C 1-4 Alkyl, -NHC(O)OC 1-4 Alkyl group, -NHC(O)NHC 1-4 Alkyl, or -NHC(O)N(C 1-4 Alkyl)2; Or, each R 6 Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, -NO2, -C(O)NH2, or optionally by one or more R 6a The following groups may be substituted: methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, -SCH3, -SCH2CH3, -NH(CH3), -NH(CH2CH3), -NCH3(CH2CH3), -N(CH2CH3)2, -C(O)CH3, -C(O)OCH3, -C(O)NHCH3, -NHC(O)CH3, -S(O)2CH3, -S(O)2NHCH3, -NHS(O)2CH3, -NHC(O)OCH3, -NHC(O)NHCH3, -NHC(O)N(CH3)2, -C(O)NH-CH2CH3, -C(O)N(CH3)2, -C(O)N(CH2CH3)2, or -C(O)N(CH3)(CH2CH3); Or, each R 6a Each is independently selected from deuterium, halogens, -NH2, -OH, -CN, and C. 1-4 Alkyl, deuterated C 1-4 Alkyl, Halogenated C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -NH(C) 1-4 alkyl), -N(C) 1-4 Alkyl)2, C 3-6 Cycloalkyl or 3-6 membered heterocyclic groups. The compound of formula (I) as claimed in any one of claims 1-8, its stereoisomers, or pharmaceutically acceptable salts thereof, wherein, When L is selected from -NH- or -C(O)NH-, R 4 Does not exist or is selected by one or more R 4b The following groups are substituted: C 6-10 Aryl, 5-10 membered heteroaryl, or 4-10 membered heterocyclic; Alternatively, when L is selected from -NH- or -C(O)NH-, R 4 It does not exist. The compound of formula (I) as claimed in any one of claims 1-9, its stereoisomers, or pharmaceutically acceptable salts thereof, wherein, When L is selected from -NH- or -C(O)NH-, R 4 It does not exist. Ring A is selected from The compound of formula (I) as claimed in any one of claims 1-10, its stereoisomers, or pharmaceutically acceptable salts thereof, wherein, m is selected from 0, 1, or 2; or, m is selected from 0; Optionally, n can be selected from 0, 1, or 2; or n can be selected from 1. The compound of formula (I) as described in any one of claims 1-11, its stereoisomers, or pharmaceutically acceptable salts thereof, is selected from compounds of formula (I'), (II-A), (II'-A), (II-B), (II'-B), (II-C), (II'-C), their stereoisomers, or pharmaceutically acceptable salts thereof. Alternatively, it may be selected from compounds of formula (III-A), (III'-A), (III-B), (III'-B), (III-C), (III'-C), their stereoisomers, or pharmaceutically acceptable salts thereof. in, R 1 R a R b R c R 3 R 4 The definitions of Y, ring A, and m are as described in any one of claims 1-11. The following compounds, their stereoisomers, or pharmaceutically acceptable salts thereof: A pharmaceutical composition comprising the compound of any one of claims 1-13, its stereoisomer, or a pharmaceutically acceptable salt thereof. The compound, stereoisomer, or pharmaceutically acceptable salt thereof, as described in any one of claims 1-13, for the treatment of diseases, or the pharmaceutical composition of claim 14; Optionally, the disease is selected from KEAP1-related diseases; or, the disease is selected from KEAP1-mediated diseases. Optionally, the KEAP1-related diseases are selected from cancer; or, the KEAP1-mediated diseases are selected from cancer.
